OBO_ID (LABEL):	CHEBI_16412 (lipopolysaccharide)

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
PMC1852384	1/2007	S47-PMC1852384	['patients were discharged on pod #2 or #3 as indicated with the following Medications: a Codeine-derivative for pain, Prenatal Vitamins, Iron Polysaccharide, Calcium Citrate, Ursodeoxycholic Acid, if the Gallbladder was present.after hospital discharge, patients were scheduled to be seen at 2 and 8\xa0weeks, 6, 12, 18, 24\xa0months, and yearly thereafter.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 73, 'medications'), ('CHEBI_16714', 'codeine', 88, 'codeine'), ('GO_0007565', 'female pregnancy', 117, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 126, 'vitamins'), ('CHEBI_16412', 'lipopolysaccharide', 136, 'iron polysaccharide'), ('CHEBI_3311', 'calcium carbonate', 157, 'calcium citrate'), ('CHEBI_85934', '(2R)-2-hydroxytetradecanoic acid', 174, 'ursodeoxycholic acid'), ('UBERON_0002110', 'gall bladder', 203, 'gallbladder')]
PMC2872320	3/2010	S250-PMC2872320	['lipopolysaccaride (Lps) is a common bacterial endotoxin.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 19, 'LPS')]
PMC2872320	3/2010	S251-PMC2872320	['Lps is typically a component of aerosoled indoor dust which includes endotoxic bacteria.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS')]
PMC2872320	3/2010	S257-PMC2872320	['in these Individuals exposure to Lps-laden dust sets off a chain of Metabolic reactions, each of which is Regulated by other Genes, which can lead to the emergence of symptoms of asthma [51–53].']	N/A	N/A	[('NCBITaxon_1', 'root', 9, 'individuals'), ('CHEBI_16412', 'lipopolysaccharide', 33, 'LPS'), ('GO_0008152', 'metabolic process', 68, 'metabolic'), ('GO_0065007', 'biological regulation', 106, 'regulated'), ('SO_0000704', 'gene', 125, 'genes')]
PMC3496584	7/2012	S23-PMC3496584	['crh, Corticotropin-Releasing Hormone; Ige, Immunoglobulin e; il, interleukin; Lps, Lipopolysaccharide; Mcp-1, Macrophage Chemo-Attractant Protein-1; mtdna, Mitochondrial Dna; nt, neurotensin; pcb, Polychlorinated Biphenyl; Ros, Reactive Oxygen Species; sp, Substance p; tnf, tumor Necrosis Factor .']	N/A	N/A	[('CHEBI_3918', 'crocetin', 5, 'corticotropin'), ('PR_000005968', 'cystatin-M', 5, 'corticotropin-releasing hormone'), ('CHEBI_33280', 'molecular messenger', 29, 'hormone'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 38, 'IgE'), ('GO_0019814', 'immunoglobulin complex', 43, 'immunoglobulin'), ('CHEBI_16412', 'lipopolysaccharide', 78, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 83, 'lipopolysaccharide'), ('PR_000010439', 'myeloid leukemia factor 1', 103, 'MCP-1'), ('CL_0000235', 'macrophage', 110, 'macrophage'), ('PR_000010430', 'MAP kinase-interacting serine/threonine-protein kinase 2', 110, 'macrophage chemo-attractant protein'), ('CHEBI_35255', 'chloroform', 121, 'chemo'), ('GO_0005739', 'mitochondrion', 156, 'mitochondrial'), ('SO_0001032', 'mitochondrial_DNA', 156, 'mitochondrial DNA'), ('CHEBI_53156', 'polychlorobiphenyl', 197, 'polychlorinated biphenyl'), ('CHEBI_8756', 'RNA (poly(A))', 223, 'ROS'), ('CHEBI_26523', 'reactive oxygen species', 228, 'reactive oxygen species'), ('CHEBI_50992', '1,3-thiazolidine-2,4-dione', 257, 'substance'), ('PR_000011040', 'nuclear receptor coactivator 1', 281, 'necrosis factor')]
PMC3496584	7/2012	S163-PMC3496584	['bacterial Lps activates Toll-Like Receptor-4 (Tlr-4) on Immune Cells leading to Synthesis and release Of Tnf [197], il-1 and Il-6 [18].']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 10, 'LPS'), ('PR_000001156', 'Toll-like receptor 5', 24, 'Toll-like receptor-4'), ('PR_000001958', 'tumor necrosis factor receptor superfamily member 1A', 46, 'TLR-4'), ('CL_0000738', 'leukocyte', 56, 'immune cells'), ('UBERON_0002405', 'immune system', 56, 'immune'), ('GO_0031047', 'gene silencing by RNA', 80, 'synthesis ... of TNF'), ('1', 'A1BG (human)', 118, '-'), ('PR_000001470', 'interleukin-28B', 125, 'IL-6')]
PMC3496584	7/2012	S173-PMC3496584	['abbreviations\nasd: autism spectrum disorders; pdd-nos: disorder-not otherwise specified; Crh: Corticotropin-Releasing Hormone; mchat: modified checklist for autism in toddlers; Lps: Lipopolysaccharide; Bbb: Blood–brain-barrier; Ros: Reactive Oxygen Species; npbi: non-protein bound iron; 3-nt: 3-Nitrotyrosine; 3Nt-3: Neurotrophin; dsm iv: diagnostic and statistical manual of mental disorders; mia: maternal Immune Activation; tlr: toll-like receptor; Tnf: Tumor Necrosis Factor; Poly(I:c): polyinosinic:Polycytidylic Acid; xmrv: xenotropic murine leukemia virus-related Virus; Csf: Cerebrospinal Fluid; Mcp-1: Macrophage Chemo-Attractant Protein-1; Tgf-Β1: Transforming Growth Factor-Beta1; nt: neurotensin; Vegf: Vascular Endothelial Growth Factor; Jak2/Stat3: Janus Tyrosine Kinase-2/Signal Transducer And Activator Of Transcription-3.']	N/A	N/A	[('PR_000005864', 'protein CREG2', 89, 'CRH'), ('CHEBI_3898', 'Cortol', 94, 'Corticotropin'), ('PR_000005959', 'cysteine and glycine-rich protein 2', 94, 'Corticotropin-releasing hormone'), ('CHEBI_16412', 'lipopolysaccharide', 177, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 182, 'Lipopolysaccharide'), ('UBERON_0006099', 'Brodmann (1909) area 1', 202, 'BBB'), ('UBERON_0000178', 'blood', 207, 'Blood–'), ('CHEBI_8756', 'RNA (poly(A))', 228, 'ROS'), ('CHEBI_26523', 'reactive oxygen species', 233, 'Reactive oxygen species'), ('CHEBI_86269', '3-nitrotyrosine', 294, '3-nitrotyrosine'), ('PR_000008757', 'heparan sulfate 2-O-sulfotransferase 1', 311, '3NT-3'), ('PR_000021998', 'neurotrophin', 318, 'Neurotrophin'), ('GO_0060819', 'inactivation of X chromosome by genetic imprinting', 409, 'immune activation'), ('UBERON_0002405', 'immune system', 409, 'immune'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 453, 'TNF'), ('PR_000016483', 'tumor necrosis factor receptor superfamily member 19', 458, 'Tumor necrosis factor'), ('CHEBI_37311', 'einsteinium molecular entity', 481, 'poly'), ('CHEBI_51686', 'haematoxylin', 486, 'I'), ('CHEBI_26206', 'polysialic acid', 505, 'polycytidylic acid'), ('NCBITaxon_1', 'root', 572, 'virus'), ('UBERON_0001359', 'cerebrospinal fluid', 579, 'CSF'), ('UBERON_0001359', 'cerebrospinal fluid', 584, 'Cerebrospinal fluid'), ('PR_000010439', 'myeloid leukemia factor 1', 605, 'MCP-1'), ('CL_0000235', 'macrophage', 612, 'Macrophage'), ('PR_000010133', 'mitogen-activated protein kinase kinase kinase 14', 612, 'Macrophage chemo-attractant protein-1'), ('PR_000000183', 'TGF-beta 2', 651, 'TGF-β1'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 659, 'Transforming growth factor-beta1'), ('PR_000017279', 'testis-specific basic protein Y 1', 710, 'VEGF'), ('PR_000017312', 'vomeronasal type-1 receptor 5', 716, 'Vascular endothelial growth factor'), ('UBERON_0001986', 'endothelium', 725, 'endothelial'), ('PR_000009211', 'lysine-specific demethylase 3A', 752, 'JAK2'), ('PR_000015700', 'alpha-2,8-sialyltransferase 8F', 757, 'STAT3'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 764, 'Janus tyrosine kinase-2'), ('PR_000015900', 'putative synaptotagmin-14-like protein', 788, 'signal transducer and activator of transcription-3')]
PMC3501517	11/2012	S4-PMC3501517	['at 8 weeks of age, Vitamin D deficient and sufficient Mice received 2.5 g/kg of Lps or saline intratracheal.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 54, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 80, 'LPS')]
PMC3501517	11/2012	S11-PMC3501517	['Vitamin D deficiency modestly impairs Neutrophil Chemotaxis; however, it does not affect Lung injury or its resolution in an Lps model of acute Lung injury.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CL_0000775', 'neutrophil', 38, 'neutrophil'), ('GO_0007567', 'parturition', 38, 'neutrophil'), ('GO_0006935', 'chemotaxis', 49, 'chemotaxis'), ('UBERON_0002048', 'lung', 89, 'lung'), ('CHEBI_16412', 'lipopolysaccharide', 125, 'LPS'), ('UBERON_0002048', 'lung', 144, 'lung')]
PMC3501517	11/2012	S44-PMC3501517	['Food Consumption was estimated by weighing Food every 2–3 days over a two-week period in 6 to 8 week-old Mice prior to Lps or pbs instillation.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Food'), ('GO_0007631', 'feeding behavior', 0, 'Food consumption'), ('CHEBI_33290', 'food', 43, 'food'), ('NCBITaxon_10088', 'Mus <genus>', 105, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 119, 'LPS')]
PMC3501517	11/2012	S46-PMC3501517	['Lps preparation\na stock Solution of Lps derived from escherichia coli o55:b5 (sigma-aldrich, st. louis, mo) in phosphate buffered saline (pbs) was stored at −20°c.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('CHEBI_75958', 'solution', 24, 'solution'), ('CHEBI_16412', 'lipopolysaccharide', 36, 'LPS')]
PMC3501517	11/2012	S47-PMC3501517	['immediately before each experiment, an aliquot of Lps was thawed, sonicated and resuspended in pbs to a working concentration of 1 mg/ml.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 50, 'LPS')]
PMC3501517	11/2012	S49-PMC3501517	['after extending the Jaw and Tongue, 2.5 µg/g body weight of Lps or an equal volume of sterile pbs was deposited in the Oropharynx with a pipette.']	N/A	N/A	[('UBERON_0001708', 'jaw skeleton', 20, 'jaw'), ('UBERON_0001723', 'tongue', 28, 'tongue'), ('CHEBI_16412', 'lipopolysaccharide', 60, 'LPS'), ('UBERON_0001729', 'oropharynx', 119, 'oropharynx')]
PMC3501517	11/2012	S52-PMC3501517	['1, 3, or 10 days after Lps or pbs instillation, Mice were anesthetized with 5% Isoflurane and underwent Tracheotomy and intubation with a blunt tip 18-gauge needle (bd bioscience, san jose, ca), which was secured with 3-0 silk suture (look, reading, pa).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 23, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 48, 'mice'), ('CHEBI_6015', 'isoflurane', 79, 'isoflurane'), ('UBERON_0001150', 'body of pancreas', 104, 'tracheotomy')]
PMC3501517	11/2012	S78-PMC3501517	['individual wells were filled with Bal Fluid from Vitamin D sufficient and deficient Mice 1 day after Lps instillation, or with various concentrations of Kc (peprotech, rocky hill, nj), C5A (r&d systems), or pbs.']	N/A	N/A	[('UBERON_0006310', 'vitelline venous plexus', 34, 'BAL fluid'), ('CHEBI_28384', 'vitamin K', 49, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 49, 'Vitamin'), ('NCBITaxon_10088', 'Mus <genus>', 84, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 101, 'LPS'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 153, 'KC'), ('PR_000002319', 'catenin beta-1 isoform 1', 185, 'C5a')]
PMC3501517	11/2012	S106-PMC3501517	['Lung injury and inflammation were measured by a variety of parameters at days 1, 3, and 10 after instillation with either pbs or Lps.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('CHEBI_16412', 'lipopolysaccharide', 129, 'LPS')]
PMC3501517	11/2012	S108-PMC3501517	['Lung injury and inflammation 1 day after Lps\nLps treatment caused significant weight loss (p<0.001) in both vds and vdd groups as compared to pbs controls.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('CHEBI_16412', 'lipopolysaccharide', 41, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 45, 'LPS')]
PMC3501517	11/2012	S110-PMC3501517	['Lung elastance was overall significantly higher after Lps treatment as compared with pbs treatment.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('CHEBI_16412', 'lipopolysaccharide', 54, 'LPS')]
PMC3501517	11/2012	S113-PMC3501517	['Lps treatment resulted in greater normalized Lung weights overall (p<0.001), but no difference was found between vds and vdd Mice 1 day after Lps treatment (2.49±0.18 vs. 2.47±0.25 mg/g, respectively) (figure 2c).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('UBERON_0002048', 'lung', 45, 'lung'), ('NCBITaxon_10088', 'Mus <genus>', 125, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 142, 'LPS')]
PMC3501517	11/2012	S115-PMC3501517	['no significant differences were observed between vds and vdd Mice after Lps treatment groups in total protein concentration (207.8±89.3 vs. 164.2±41.9 µg/ml) or Igm concentration (108.2±79.2 vs. 82.1±43.6 ng/ml)(figure 2d, 2e).10.1371/journal.pone.0049076.g002\n\ncaption (fig): figure 2\nLung injury 1 day after Lps instillation.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 61, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 72, 'LPS'), ('GO_0071754', 'IgM immunoglobulin complex, circulating', 161, 'IgM'), ('UBERON_0002048', 'lung', 286, 'Lung'), ('CHEBI_16412', 'lipopolysaccharide', 310, 'LPS')]
PMC3501517	11/2012	S116-PMC3501517	['Vitamin D-sufficient (vds) or –deficient (vdd) treated with either Lps or pbs.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 67, 'LPS')]
PMC3501517	11/2012	S120-PMC3501517	['in contrast to measurements of Lung mechanics and permeability, total Bal Fluid Leukocyte count was modestly higher after Lps treatment in vds versus vdd Mice (2.0±0.54×105vs.']	N/A	N/A	[('UBERON_0002048', 'lung', 31, 'lung'), ('UBERON_0006310', 'vitelline venous plexus', 70, 'BAL fluid'), ('CL_0000738', 'leukocyte', 80, 'leukocyte'), ('CHEBI_16412', 'lipopolysaccharide', 122, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 154, 'mice')]
PMC3501517	11/2012	S124-PMC3501517	['minimal Bal Fluid Lymphocytes were observed in both vds and vdd Mice treated with Lps (0.04±0.06×104vs.']	N/A	N/A	[('UBERON_0006310', 'vitelline venous plexus', 8, 'BAL fluid'), ('CL_0000542', 'lymphocyte', 18, 'lymphocytes'), ('NCBITaxon_10088', 'Mus <genus>', 64, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 82, 'LPS')]
PMC3501517	11/2012	S128-PMC3501517	['Vitamin D-sufficient (vds) or –deficient (vdd) treated with either Lps or pbs.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 67, 'LPS')]
PMC3501517	11/2012	S130-PMC3501517	['( a ) Bronchoalveolar Lavage (Bal) fluid total cell count, p<0.05 comparing vds and vdd Mice after Lps instillation; ( b ) Bal Fluid Neutrophil count, p\u200a=\u200a0.09 comparing vds and vdd Mice after Lps; ( c ) Bal Fluid Kc/Cxcl1 concentration; ( d ) Bal Fluid Mip2/Cxcl2 concentration.']	N/A	N/A	[('UBERON_0006326', 'base of arytenoid', 6, 'Bronchoalveolar lavage'), ('UBERON_0006378', 'strand of vibrissa hair', 30, 'BAL'), ('NCBITaxon_10088', 'Mus <genus>', 88, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 99, 'LPS'), ('UBERON_0006310', 'vitelline venous plexus', 123, 'BAL fluid'), ('CL_0000775', 'neutrophil', 133, 'neutrophil'), ('NCBITaxon_10088', 'Mus <genus>', 182, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 193, 'LPS'), ('UBERON_0006310', 'vitelline venous plexus', 204, 'BAL fluid'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 214, 'KC'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 217, 'CXCL1'), ('UBERON_0006310', 'vitelline venous plexus', 244, 'BAL fluid'), ('PR_000010430', 'MAP kinase-interacting serine/threonine-protein kinase 2', 254, 'MIP2'), ('PR_000006079', 'cytochrome b5 type B', 259, 'CXCL2')]
PMC3501517	11/2012	S131-PMC3501517	['Lung histological sections demonstrate mildly increased cellularity in both vds and vdd Mice one day after Lps exposure as compared to pbs-exposed Animals (figure 4).']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('NCBITaxon_10088', 'Mus <genus>', 88, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 107, 'LPS'), ('NCBITaxon_33208', 'Metazoa', 147, 'animals')]
PMC3501517	11/2012	S134-PMC3501517	['400× magnfication of Hematoxylin and eosin stained sections of Right Lung Lobes collected from Vitamin D sufficient (vds) and deficient (vdd) Mice after exposure to pbs or to Lps for varying lengths of time.']	N/A	N/A	[('CHEBI_51686', 'haematoxylin', 21, 'hematoxylin'), ('UBERON_0006518', 'right lung lobe', 63, 'right lung lobes'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 142, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 175, 'LPS')]
PMC3501517	11/2012	S138-PMC3501517	['Lung Elastance was elevated after Lps treatment as compared with pbs treatment but there was no significant difference between the vds and vdd Mice (37.9±4.8 vs. 34.5±4.0 cmh2o/ml) (figure 5b).10.1371/journal.pone.0049076.g005\n\ncaption (fig): figure 5\nLung injury and inflammation 3 days after Lps instillation.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('GO_0050956', 'electroception', 5, 'elastance'), ('CHEBI_16412', 'lipopolysaccharide', 34, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 143, 'mice'), ('UBERON_0002048', 'lung', 252, 'Lung'), ('CHEBI_16412', 'lipopolysaccharide', 294, 'LPS')]
PMC3501517	11/2012	S139-PMC3501517	['Vitamin D-sufficient (vds) or –deficient (vdd) treated with either Lps or pbs.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 67, 'LPS')]
PMC3501517	11/2012	S142-PMC3501517	['permeability was not different between vds and vdd Mice 3 days after Lps.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 51, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 69, 'LPS')]
PMC3501517	11/2012	S150-PMC3501517	['Bal Fluid cytokine levels of Kc/Cxcl1, Mip2/Cxcl2, tnfα and Il6 were not significantly different between vdd and vds Mice 3 days after Lps administration (data not shown).']	N/A	N/A	[('UBERON_0006310', 'vitelline venous plexus', 0, 'BAL fluid'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 29, 'KC'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 32, 'CXCL1'), ('PR_000010430', 'MAP kinase-interacting serine/threonine-protein kinase 2', 39, 'MIP2'), ('PR_000006079', 'cytochrome b5 type B', 44, 'CXCL2'), ('PR_000008989', 'interleukin-1 family member 7', 60, 'IL6'), ('NCBITaxon_10088', 'Mus <genus>', 117, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 135, 'LPS')]
PMC3501517	11/2012	S155-PMC3501517	['Vitamin D-sufficient (vds) or –deficient (vdd) were treated with either Lps or pbs.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 72, 'LPS')]
PMC3501517	11/2012	S157-PMC3501517	['( a ) percent body weight change, p<0.05 comparing vds and vdd Mice after Lps; ( b ) Lung elastance (h) over time following Lung recruitment (mean ± sem); ( c ) Left Lung Lobe weight (wt) normalized to day 0 body weight; ( d ) total protein concentration of Bronchoalveolar Lavage (Bal) Fluid; ( e ) Igm concentration of Bal Fluid; ( f ) Bal Fluid total cell count; ( g ) bal Neutrophil count.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 63, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 74, 'LPS'), ('UBERON_0002048', 'lung', 85, 'Lung'), ('UBERON_0002048', 'lung', 124, 'lung'), ('UBERON_0008951', 'left lung lobe', 161, 'Left lung lobe'), ('UBERON_0013561', 'Brodmann (1909) area 43', 258, 'bronchoalveolar lavage ...'), ('UBERON_0002436', 'primary visual cortex', 282, 'BAL ...'), ('UBERON_0006314', 'bodily fluid', 287, 'fluid'), ('GO_0071754', 'IgM immunoglobulin complex, circulating', 300, 'IgM'), ('UBERON_0006310', 'vitelline venous plexus', 321, 'BAL fluid'), ('UBERON_0006310', 'vitelline venous plexus', 338, 'BAL fluid'), ('CL_0000775', 'neutrophil', 376, 'neutrophil')]
PMC3501517	11/2012	S158-PMC3501517	['Lung inflammation and injury had resolved to a similar degree in both vds and vdd Mice by day 10 following Lps instillation.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('NCBITaxon_10088', 'Mus <genus>', 82, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 107, 'LPS')]
PMC3501517	11/2012	S163-PMC3501517	['0.96±0.36×105cells) were all statistically similar between Lps-treated vds and vdd Mice.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 59, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 83, 'mice')]
PMC3501517	11/2012	S171-PMC3501517	['( a ) vds Neutrophil Chemotaxis towards Bal Fluid collected from vds and vdd Mice 1 day after Lps stimulation; Chemotaxis of Neutrophils isolated from vds and vdd Mice towards varying concentrations of ( b ) Kc/Cxcl1 (n\u200a=\u200a5 per group) and ( c ) Complement C5A (n\u200a=\u200a3 per group); ( d ) percentage of Cxcr2 positive cells in Neutrophils isolated from Bone Marrow of vds and vdd Mice (n\u200a=\u200a4 per group); ( e ) Expression of Cxcr2 as determined by mean fluorescent intensity measured with flow cytometry of Cxcr2+ cells from Bone Marrow of vds and vdd Mice (n\u200a=\u200a4 per group).']	N/A	N/A	[('CL_0000775', 'neutrophil', 10, 'neutrophil'), ('GO_0007567', 'parturition', 10, 'neutrophil'), ('GO_0006935', 'chemotaxis', 21, 'chemotaxis'), ('UBERON_0006310', 'vitelline venous plexus', 40, 'BAL fluid'), ('NCBITaxon_10088', 'Mus <genus>', 77, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 94, 'LPS'), ('GO_0006935', 'chemotaxis', 111, 'Chemotaxis'), ('CL_0000775', 'neutrophil', 125, 'neutrophils'), ('NCBITaxon_10088', 'Mus <genus>', 163, 'mice'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 208, 'KC'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 211, 'CXCL1'), ('PR_000004900', 'complement C3', 245, 'complement C5a'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 299, 'CXCR2'), ('CL_0000775', 'neutrophil', 323, 'neutrophils'), ('UBERON_0002371', 'bone marrow', 349, 'bone marrow'), ('NCBITaxon_10088', 'Mus <genus>', 376, 'mice'), ('GO_0010467', 'gene expression', 406, 'Expression'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 420, 'CXCR2'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 502, 'CXCR2'), ('UBERON_0002371', 'bone marrow', 520, 'bone marrow'), ('NCBITaxon_10088', 'Mus <genus>', 547, 'mice')]
PMC3501517	11/2012	S187-PMC3501517	['Lung injury as measured by wet Lung weight, elastance, and permeability was greatest three days following Lps exposure without any difference seen between vds and vdd Mice for any measured parameter, including Bal Fluid Leukocytes.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('UBERON_0002048', 'lung', 31, 'lung'), ('CHEBI_16412', 'lipopolysaccharide', 106, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 167, 'mice'), ('UBERON_0006310', 'vitelline venous plexus', 210, 'BAL fluid'), ('CL_0000738', 'leukocyte', 220, 'leukocytes')]
PMC3527219	11/2012	S4-PMC3527219	['Cortisol, total protein, Immunoglobulins, Lymphocyte Proliferation, Immune Cell counts, and cytokines were assessed in the Blood of offspring at baseline and under challenging conditions (weaning; Lipopolysaccharide (Lps) administration).']	N/A	N/A	[('CHEBI_17650', 'cortisol', 0, 'Cortisol'), ('GO_0019814', 'immunoglobulin complex', 25, 'immunoglobulins'), ('CL_0000542', 'lymphocyte', 42, 'lymphocyte'), ('GO_0046651', 'lymphocyte proliferation', 42, 'lymphocyte proliferation'), ('CL_0000738', 'leukocyte', 68, 'immune cell'), ('UBERON_0002405', 'immune system', 68, 'immune'), ('UBERON_0000178', 'blood', 123, 'blood'), ('CHEBI_16412', 'lipopolysaccharide', 197, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 217, 'LPS')]
PMC3527219	11/2012	S9-PMC3527219	['the Lipopolysaccharide-induced rise of Il-6 was higher in lp ( p \u2009=\u20090.09) and hp ( p \u2009<\u20090.01) compared with ap piglets, and lp piglets displayed higher Il-10 levels than ap piglets ( p \u2009<\u20090.05).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 4, 'lipopolysaccharide'), ('PR_000001470', 'interleukin-28B', 39, 'IL-6'), ('PR_000001470', 'interleukin-28B', 152, 'IL-10')]
PMC3527219	11/2012	S62-PMC3527219	['injection of Lps from escherichia coli (serotype o111:b4, sigma chemical company, st. louis, mo, usa) at a dose of 100 μg/kg of body weight dissolved in 2 ml sterile saline.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC3527219	11/2012	S63-PMC3527219	['Blood samples were taken immediately before Lps injection (0h, baseline for all measures), 1 h later for analysis of Tnf-Α, and 3 and 6 h later to measure Cortisol and cytokines (Tnf-Α, Il-6 and Il-10).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_16412', 'lipopolysaccharide', 44, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 117, 'TNF-α'), ('CHEBI_17650', 'cortisol', 155, 'cortisol'), ('PR_000000134', 'tumor necrosis factor alpha', 179, 'TNF-α'), ('PR_000001470', 'interleukin-28B', 186, 'IL-6'), ('PR_000001470', 'interleukin-28B', 195, 'IL-10')]
PMC3527219	11/2012	S76-PMC3527219	['the Mitogens Concanavalin A (5 μg/ml; cona) and Lipopolysaccharide (10 μg/ml; Lps) were used in Lymphocyte Proliferation/viability assays as previously described [28].']	N/A	N/A	[('CHEBI_52290', 'mitogen', 4, 'mitogens'), ('CHEBI_69856', 'Cosmosporaside B', 13, 'Concanavalin A'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 78, 'LPS'), ('CL_0000542', 'lymphocyte', 96, 'lymphocyte'), ('GO_0008283', 'cell proliferation', 107, 'proliferation')]
PMC3527219	11/2012	S138-PMC3527219	['further, there was no significant effect of maternal diet on the number of Pbmcs or the Mitogen-induced Pbmc Proliferation in response to either cona or Lps in piglets at d1 and d27 of age ( p \u2009>\u20090.2; data not shown).']	N/A	N/A	[('CL_0002246', 'peripheral blood stem cell', 75, 'PBMCs'), ('CHEBI_52290', 'mitogen', 88, 'mitogen'), ('CL_0002246', 'peripheral blood stem cell', 104, 'PBMC'), ('GO_0008283', 'cell proliferation', 109, 'proliferation'), ('CHEBI_16412', 'lipopolysaccharide', 153, 'LPS')]
PMC3527219	11/2012	S152-PMC3527219	['the Lymphocyte Proliferation in response to both Mitogens cona and Lps was not influenced by maternal diet and diet\u2009×\u2009sampling time interaction ( p \u2009>\u20090.21).']	N/A	N/A	[('CL_0000542', 'lymphocyte', 4, 'lymphocyte'), ('GO_0046651', 'lymphocyte proliferation', 4, 'lymphocyte proliferation'), ('CHEBI_52290', 'mitogen', 49, 'mitogens'), ('CHEBI_16412', 'lipopolysaccharide', 67, 'LPS')]
PMC3527219	11/2012	S155-PMC3527219	['caption (fig): figure 4\n\nLymphocyte Proliferation indices (pi) in response to cona (a) and Lps (b) in weaned Piglets.']	N/A	N/A	[('CL_0000824', 'mature natural killer cell', 25, 'Lymphocyte'), ('GO_0070340', 'detection of bacterial lipopeptide', 25, 'Lymphocyte proliferation'), ('CHEBI_16412', 'lipopolysaccharide', 91, 'LPS'), ('NCBITaxon_33208', 'Metazoa', 109, 'piglets')]
PMC3527219	11/2012	S168-PMC3527219	['effects of maternal diet on offspring response to Lps challenge\nIntraperitoneal injection of 100 μg Lps/kg body weight induced significant increases in the Plasma concentration of Tnf-α 1 h later (figure\u20096b) and in concentrations of Cortisol (figure\u20096a), Il-6 (figure\u20096c) and Il-10 (figure\u20096d) 3 h after Lps in Piglets on day 47 ( p \u2009<\u20090.001).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 50, 'LPS'), ('UBERON_0007158', 'lumen of anal canal', 64, 'Intraperitoneal'), ('CHEBI_16412', 'lipopolysaccharide', 100, 'LPS'), ('UBERON_0001969', 'blood plasma', 156, 'plasma'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 180, 'TNF'), ('CHEBI_17650', 'cortisol', 233, 'cortisol'), ('PR_000001470', 'interleukin-28B', 255, 'IL-6'), ('PR_000001470', 'interleukin-28B', 276, 'IL-10'), ('CHEBI_16412', 'lipopolysaccharide', 304, 'LPS'), ('NCBITaxon_33208', 'Metazoa', 311, 'piglets')]
PMC3527219	11/2012	S170-PMC3527219	['three hours after the challenge, lp and hp piglets responded to Lps with higher Il-6 concentrations than ap piglets (p\u2009=\u20090.09 and p\u2009<\u20090.01, respectively).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 64, 'LPS'), ('PR_000001470', 'interleukin-28B', 80, 'IL-6')]
PMC3527219	11/2012	S173-PMC3527219	['caption (fig): figure 6\n\nPlasma Cortisol (a), Tnf-Α (b), Il-6 (c) and Il-10 (d) concentrations in Pigs challenged with Lps.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 25, 'Plasma'), ('CHEBI_17650', 'cortisol', 32, 'cortisol'), ('PR_000000134', 'tumor necrosis factor alpha', 46, 'TNF-α'), ('PR_000001470', 'interleukin-28B', 57, 'IL-6'), ('PR_000001470', 'interleukin-28B', 70, 'IL-10'), ('NCBITaxon_10088', 'Mus <genus>', 98, 'pigs'), ('CHEBI_16412', 'lipopolysaccharide', 119, 'LPS')]
PMC3527219	11/2012	S176-PMC3527219	['injection of Lps from escherichia coli (serotype o111:b4) at a dose of 100 μg/kg of body weight.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC3527219	11/2012	S177-PMC3527219	['Blood samples were taken before (0 h) and after Lps challenge (1 h, 3 h, 6 h).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'LPS')]
PMC3527219	11/2012	S209-PMC3527219	['after Lps challenge, there was no effect of inadequate dietary protein to Carbohydrate ratios on Cortisol release.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 6, 'LPS'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 74, 'carbohydrate'), ('CHEBI_17650', 'cortisol', 97, 'cortisol')]
PMC3527219	11/2012	S212-PMC3527219	['[9], where Prenatal stress also did not affect Cortisol levels of Piglets in response to Lps.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'prenatal'), ('CHEBI_17650', 'cortisol', 47, 'cortisol'), ('NCBITaxon_33208', 'Metazoa', 66, 'piglets'), ('CHEBI_16412', 'lipopolysaccharide', 89, 'LPS')]
PMC3527219	11/2012	S237-PMC3527219	['abbreviations\nap: adequate protein; cona: concanavalin a; gd: Gestation day; hp: high protein; lp: low protein; Lps: Lipopolysaccharide; pbmc: Peripheral Blood Mononuclear Cells.']	N/A	N/A	[('GO_0006266', 'DNA ligation', 62, 'Gestation'), ('CHEBI_16412', 'lipopolysaccharide', 112, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 117, 'Lipopolysaccharide'), ('CL_0000111', 'peripheral neuron', 143, 'Peripheral blood mononuclear cells'), ('UBERON_0000178', 'blood', 154, 'blood'), ('GO_0031097', 'medial cortex', 160, 'mononuclear')]
PMC3608729	3/2013	S16-PMC3608729	['the diets in that study included those low in protein relative to Sugar (Lps) as well as high in protein relative to Sugar (hps).']	N/A	N/A	[('CHEBI_24870', 'ion', 66, 'sugar'), ('CHEBI_16412', 'lipopolysaccharide', 73, 'LPS'), ('CHEBI_24870', 'ion', 117, 'sugar')]
PMC3608729	3/2013	S17-PMC3608729	['in the Lps diet the ratio of Sugar to protein was 9.8 compared to 2.6 for the hps diet, and it produced emerging Adults with significantly higher Metabolic pools of Triglycerides and Glycogen relative to those reared on hps.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 7, 'LPS'), ('CHEBI_24870', 'ion', 29, 'sugar'), ('UBERON_0007023', 'adult organism', 113, 'adults'), ('GO_0008152', 'metabolic process', 146, 'metabolic'), ('CHEBI_17855', 'triglyceride', 165, 'triglycerides'), ('CHEBI_24384', 'glycogens', 183, 'glycogen')]
PMC3608729	3/2013	S24-PMC3608729	['to address these questions, we reared Individuals of five isofemale strains on the two diets, Lps and hps, described above.']	N/A	N/A	[('NCBITaxon_1', 'root', 38, 'individuals'), ('CHEBI_16412', 'lipopolysaccharide', 94, 'LPS')]
PMC3608729	3/2013	S29-PMC3608729	['hps refers to the diet high in protein and low in Sugar, while the low protein, high sugar diet is denoted by Lps.']	N/A	N/A	[('CHEBI_24870', 'ion', 50, 'sugar'), ('CHEBI_16412', 'lipopolysaccharide', 110, 'LPS')]
PMC3608729	3/2013	S42-PMC3608729	['Adults (f1) from each of the isofemale lines and parental diets (Hps or Lps) emerging from the standard banana Food were then separated as virgins using co2anesthesia.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 0, 'Adults'), ('CHEBI_17883', 'hydrogen chloride', 65, 'HPS'), ('CHEBI_16412', 'lipopolysaccharide', 72, 'LPS'), ('CHEBI_33290', 'food', 111, 'food')]
PMC3608729	3/2013	S73-PMC3608729	['flies whose parents developed on the hps diet had a metamorphic stage that lasted four days, while Flies whose parents were raised on the Lps diet had a significantly longer Metamorphic Stage (4.48±0.08 days).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 99, 'flies'), ('CHEBI_16412', 'lipopolysaccharide', 138, 'LPS'), ('UBERON_0003220', 'metanephric mesenchyme', 174, 'metamorphic stage')]
PMC3608729	3/2013	S83-PMC3608729	['values (means ± standard errors) are given for each isofemale line (numbers 1, 2, 3, 5 and 6) and sex, f\u200a=\u200afemale and m\u200a=\u200amale.10.1371/journal.pone.0059530.t003\n\ncaption (table-wrap): table 3\nanova of dry mass for f1from isofemale lines of d. melanogaster raised on larval diets Hps and Lps.source df ssf ratioparental diet11.96287***line40.76228.0***sex122.23262***parental diet × line40.65624.1***parental diet × sex11.98292***line × sex40.90433.3***parental diet × line × sex40.28310.4***error1901.29total20931.6\np<0.05,\np<0.01,\np<0.001.']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 279, 'HPS'), ('CHEBI_16412', 'lipopolysaccharide', 287, 'LPS')]
PMC3608729	3/2013	S91-PMC3608729	['sex was not a significant factor, and similar results were observed when partitioning the analysis by sex (table s5).10.1371/journal.pone.0059530.t005\n\ncaption (table-wrap): table 5\nanova of Glycogen content for f1from isofemale lines of d. melanogaster raised on larval diets Hps and Lps.source df ssf ratioparental diet10.165184.3***line40.117215.0***sex10.00341.73 nsparental diet × line40.155119.8***parental diet × sex10.00321.62 nsline × sex40.05006.38***parental diet × line × sex40.00801.01 nserror1900.3722total2090.8914\np<0.05,\np<0.01,\np<0.001.']	N/A	N/A	[('CHEBI_24384', 'glycogens', 191, 'glycogen'), ('CHEBI_17883', 'hydrogen chloride', 277, 'HPS'), ('CHEBI_16412', 'lipopolysaccharide', 285, 'LPS')]
PMC3608729	3/2013	S96-PMC3608729	['(table s6).10.1371/journal.pone.0059530.t006\n\ncaption (table-wrap): table 6\nanova of Triglyceride content for f1from isofemale lines of d. melanogaster raised on larval diets Hps and Lps.source df ssf ratioparental diet10.035029.3***line40.04258.91***sex10.00463.82parental diet × line40.01142.39parental diet × sex10.00010.05line × sex40.01412.96*parental diet × line × sex40.00070.15error1900.2264total2090.3497\np<0.05,\np<0.01,\np<0.001.']	N/A	N/A	[('CHEBI_17855', 'triglyceride', 85, 'triglyceride'), ('CHEBI_17883', 'hydrogen chloride', 175, 'HPS'), ('CHEBI_16412', 'lipopolysaccharide', 183, 'LPS')]
PMC3608729	3/2013	S105-PMC3608729	['parents reared on the Lps diet had lower Metabolic pools of protein compared to those reared on high protein and the same was true of their offspring.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 22, 'LPS'), ('GO_0008152', 'metabolic process', 41, 'metabolic')]
PMC3608729	3/2013	S106-PMC3608729	['the Lps diet produced parents that had high levels of Glycogen compared to the hps parents and their offspring differed from each other in the same direction.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 4, 'LPS'), ('CHEBI_24384', 'glycogens', 54, 'glycogen')]
PMC3608729	3/2013	S142-PMC3608729	['supporting information\n\ncaption (supplementary-material): figure s1\n\nisofemale line mean (± standard error) four-day fecundity for the parents (p) raised on the Hps or Lps diets and their offspring (f1) who were raised in a common standard banana diet.']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 161, 'HPS'), ('CHEBI_16412', 'lipopolysaccharide', 168, 'LPS')]
PMC3668200	5/2013	S7-PMC3668200	['in the Kidney, 25(Oh)D, the nutritional indicator of Vitamin D, is hydroxylated into 1,25-Dihydroxyvitamin D (1,25-Oh2-d).']	N/A	N/A	[('UBERON_0002113', 'kidney', 7, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 85, '1,25-dihydroxyvitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 115, 'OH2')]
PMC3699531	7/2013	S6-PMC3699531	['differentiated Bone Marrow Macrophages (bmm) were stimulated with Lps (100 ng/ml) for 6 h. Uns-derived Bmm had significantly increased secretion and Expression of Il-1Β and Il-6 following Lps stimulation.']	N/A	N/A	[('CL_0002476', 'bone marrow macrophage', 15, 'bone marrow macrophages'), ('UBERON_0002371', 'bone marrow', 15, 'bone marrow'), ('CHEBI_16412', 'lipopolysaccharide', 66, 'LPS'), ('UBERON_0000164', 'primitive urogenital sinus', 91, 'UNS'), ('UBERON_0003002', 'medial lemniscus', 103, 'BMM'), ('GO_0010467', 'gene expression', 149, 'expression'), ('PR_000001383', 'interleukin-22', 163, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 173, 'IL-6'), ('CHEBI_16412', 'lipopolysaccharide', 188, 'LPS')]
PMC3699531	7/2013	S50-PMC3699531	['following 7 d culture cells were stimulated for 6 h with Lipopolysaccharide (Lps) (100 ng/ml) for cytokine and rna analysis.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 57, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 77, 'LPS')]
PMC3699531	7/2013	S58-PMC3699531	['statistics\nthree way-analysis of variance (anova) was used to determine significant differences in bmm between conditions with maternal diet, pre-weaning gh treatment and Lps stimulation as factors.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 171, 'LPS')]
PMC3699531	7/2013	S73-PMC3699531	['Bmm cytokine profile\nfollowing stimulation with Lps, there were significantly enhanced Il-1Β and Il-6 concentrations in uns compared to cs, cgh and ungh-derived Bmm (figure 2a&b).']	N/A	N/A	[('PR_000000034', 'BMP', 0, 'BMM'), ('UBERON_0003002', 'medial lemniscus', 0, 'BMM'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'LPS'), ('PR_000001383', 'interleukin-22', 87, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 97, 'IL-6'), ('UBERON_0003002', 'medial lemniscus', 161, 'BMM')]
PMC3699531	7/2013	S77-PMC3699531	['once differentiated bmm were stimulated for 6 h with Lps (100 ng/ml).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 53, 'LPS')]
PMC3699531	7/2013	S86-PMC3699531	['once differentiated bmm were stimulated for 6 h with Lps (100 ng/ml).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 53, 'LPS')]
PMC3699531	7/2013	S90-PMC3699531	['Bmm polarization potential\nin response to Lps stimulation uns-derived Bmm demonstrated significantly increased Cd11C Expression compared to cs, cgh and ungh (figure 4a).']	N/A	N/A	[('UBERON_0003002', 'medial lemniscus', 0, 'BMM'), ('CHEBI_16412', 'lipopolysaccharide', 42, 'LPS'), ('UBERON_0003002', 'medial lemniscus', 70, 'BMM'), ('PR_000001309', 'CD70 molecule', 111, 'CD11c'), ('GO_0010467', 'gene expression', 117, 'expression')]
PMC3699531	7/2013	S97-PMC3699531	['once differentiated, bmm were stimulated for 6 h with Lps (100 ng/ml).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 54, 'LPS')]
PMC3740243	8/2013	S47-PMC3740243	['they also have reduced Expression of the pathogen-associated molecular pattern receptor, Toll-Like Receptor (Tlr)4, mrna and an attenuated pro-inflammatory response to stimulation with Lipopolysaccharide (Lps) than those not given the b. fragilis supplements (gronlund et al.,2000; sjogren et al.,2009).']	N/A	N/A	[('GO_0010467', 'gene expression', 23, 'expression'), ('PR_000001708', 'sphingosine 1-phosphate receptor 3', 89, 'toll-like receptor ...'), ('PR_000001708', 'sphingosine 1-phosphate receptor 3', 109, 'TLR ... 4'), ('CHEBI_16412', 'lipopolysaccharide', 185, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 205, 'LPS')]
PMC3740243	8/2013	S132-PMC3740243	['in neonatally overfed Rats the response to Lps is exacerbated, while the response to polyi:c remains normal (clarke et al.,2012).']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 22, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 43, 'LPS')]
PMC3740243	8/2013	S154-PMC3740243	['early Life immune challenge leads to an exacerbated hpa axis response to Lps in later Life and blocking this increase with Ru486 can restore a normal febrile response and cytokine profile (ellis et al.,2005; mouihate et al.,2010).']	N/A	N/A	[('UBERON_0000104', 'life cycle', 6, 'life'), ('CHEBI_16412', 'lipopolysaccharide', 73, 'LPS'), ('UBERON_0000104', 'life cycle', 86, 'life'), ('CHEBI_82004', 'R1128D', 123, 'RU486')]
PMC3740243	8/2013	S166-PMC3740243	['in neonatally overfed Rats, Adult Lps leads to a significantly enhanced pvn response to stress and a Corticosterone response that is significantly less efficient.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 22, 'rats'), ('UBERON_0007023', 'adult organism', 28, 'adult'), ('CHEBI_16412', 'lipopolysaccharide', 34, 'LPS'), ('CHEBI_16827', 'corticosterone', 101, 'corticosterone')]
PMC3773449	8/2013	S133-PMC3773449	['in Sheep, chorioamnionitis induced by intra-amniotic injection of Lipopolysaccharides (Lps) at Embryonic days e121 reduced fetal Nephron number by 20% [110].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 3, 'sheep'), ('CHEBI_16412', 'lipopolysaccharide', 66, 'lipopolysaccharides'), ('CHEBI_16412', 'lipopolysaccharide', 87, 'LPS'), ('UBERON_0000922', 'embryo', 95, 'embryonic'), ('UBERON_0001285', 'nephron', 129, 'nephron')]
PMC3773919	9/2013	S244-PMC3773919	['Lpr-treated Mice exhibited significantly lower clinical symptoms of dermatitis and reduced scratching frequency, compared with untreated Mice.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPR'), ('NCBITaxon_10088', 'Mus <genus>', 12, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 137, 'mice')]
PMC3820434	12/2012	S196-PMC3820434	['moreover, cd14 knockout Rats showing reduced inflammatory reaction to Lps were immune to weight gain [88].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 24, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 70, 'LPS')]
PMC4129499	8/2014	S195-PMC4129499	['markers under consideration include circulating Antibodies against Tight Junction proteins, Lps, actomyosin (145) calprotectin (146), and Lactoferrin (147).']	N/A	N/A	[('GO_0042571', 'immunoglobulin complex, circulating', 48, 'antibodies'), ('GO_0044292', 'dendrite terminus', 67, 'tight junction'), ('CHEBI_16412', 'lipopolysaccharide', 92, 'LPS'), ('PR_000002198', 'catenin beta-1', 138, 'lactoferrin')]
PMC4142706	7/2014	S33-PMC4142706	['ssbs are easily induced by a brief treatment with H2O2Or by irradiation with x- or γ-rays; oxidized Purines, mainly 8-Oxog, are induced by treating the cells with the photosensitiser ro 19-8022 plus visible light; alkylated bases are produced by treating the cells with an alkylating agent such as methyl Methanesulfonate (Mms) and Dimerized pyrimidines are produced by irradiating the cells with uv(c).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 50, 'H2O2or'), ('CHEBI_35875', 'imidazopyrimidine', 100, 'purines'), ('CHEBI_79381', 'A-factor', 116, '8-oxoG'), ('CHEBI_25224', 'methanesulfonate', 305, 'methanesulfonate'), ('CHEBI_39010', 'MES', 323, 'MMS'), ('GO_0004654', 'polyribonucleotide nucleotidyltransferase activity', 332, 'dimerized')]
PMC4203464	10/2014	S34-PMC4203464	['Hmos are broken down into Short-Chain Fatty Acids that promote the growth of bifidobacteria and lactobacillus [20].']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'HMOs'), ('CHEBI_26666', 'short-chain fatty acid', 26, 'short-chain fatty acids')]
PMC4203464	10/2014	S183-PMC4203464	['abbreviations\nasd: autism spectrum disorder; c-section: caesarean section; Dcs: Dendritic Cells; galt: Gut-Associated Lymphoid Tissue; Hscrp: high-Sensitivity C-Reactive Protein; Lps: Lipopolysaccharide; mamps: microbe-associated molecular patterns; nec: necrotizing enterocolitis; nicu: Neonatal Intensive Care unit; ptb: Preterm Birth; Siga: Secretory Immunoglobulin A; tlrs: toll-like receptors; vlbw: very low Birth weight.']	N/A	N/A	[('CL_0000990', 'conventional dendritic cell', 75, 'DCs'), ('CL_0000451', 'dendritic cell', 80, 'dendritic cells'), ('GO_0030425', 'dendrite', 80, 'dendritic'), ('UBERON_0001962', 'gut-associated lymphoid tissue', 103, 'gut-associated lymphoid tissue'), ('PR_P07992', 'DNA excision repair protein ERCC-1 (human)', 135, 'hsCRP'), ('PR_000015609', 'steroid 5-alpha-reductase 2-like 2 protein', 147, 'sensitivity C-reactive protein'), ('CHEBI_16412', 'lipopolysaccharide', 179, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 184, 'lipopolysaccharide'), ('UBERON_0001759', 'vagus nerve', 288, 'neonatal'), ('UBERON_0001007', 'digestive system', 297, 'intensive care'), ('GO_0007565', 'female pregnancy', 323, 'preterm'), ('GO_0007567', 'parturition', 331, 'birth'), ('PR_000000364', 'smad2', 338, 'SIgA'), ('PR_000014450', 'histone deacetylase complex subunit SAP30L', 344, 'secretory immunoglobulin A'), ('GO_0019814', 'immunoglobulin complex', 354, 'immunoglobulin'), ('GO_0007567', 'parturition', 414, 'birth')]
PMC4214174	9/2014	S50-PMC4214174	['(b) Adult offspring of dams Fed a hfd had increased body weight and leptin, along with increased basal and Lps-induced proinflammatory cytokine (interleukin-1β) concentrations within the hippocampus.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 4, 'Adult'), ('GO_0007631', 'feeding behavior', 28, 'fed'), ('CHEBI_16412', 'lipopolysaccharide', 107, 'LPS')]
PMC4258799	11/2014	S191-PMC4258799	['reduced Mda concentration (less Lpo in Spermatozoa)suleiman et al.']	N/A	N/A	[('CHEBI_34840', 'methyl methacrylate', 8, 'MDA'), ('CHEBI_16412', 'lipopolysaccharide', 32, 'LPO'), ('CL_0000019', 'sperm', 39, 'spermatozoa')]
PMC4258799	11/2014	S198-PMC4258799	['reduced Mda concentration (less Lpo in Spermatozoa)keskes-ammar et al.']	N/A	N/A	[('CHEBI_34840', 'methyl methacrylate', 8, 'MDA'), ('CHEBI_16412', 'lipopolysaccharide', 32, 'LPO'), ('CL_0000019', 'sperm', 39, 'spermatozoa')]
PMC4258799	11/2014	S227-PMC4258799	['decreased 8-Isoprostane levels (biomarker of Lpo) (attenuation of os in Seminal Plasma)3.']	N/A	N/A	[('CHEBI_35870', 'diarsenide', 10, '8-isoprostane'), ('CHEBI_16412', 'lipopolysaccharide', 45, 'LPO'), ('UBERON_0006530', 'seminal fluid', 72, 'seminal plasma')]
PMC4263713	12/2014	S5-PMC4263713	['the Intestinal levels of secretory Immunoglobulin a and Polymeric Immunoglobulin receptor increased significantly with Lipopolysaccharide challenge in the Rats that received Vitamin A supplementation starting on Postnatal day 1.']	N/A	N/A	[('UBERON_0000160', 'intestine', 4, 'intestinal'), ('GO_0019814', 'immunoglobulin complex', 35, 'immunoglobulin'), ('CHEBI_33839', 'macromolecule', 56, 'polymeric'), ('GO_0019814', 'immunoglobulin complex', 66, 'immunoglobulin'), ('CHEBI_16412', 'lipopolysaccharide', 119, 'lipopolysaccharide'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 155, 'rats'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin A'), ('GO_0007567', 'parturition', 212, 'postnatal')]
PMC4263713	12/2014	S29-PMC4263713	['materials and methods\n\nAnimals, diets and Lipopolysaccharide challenge\ntwenty spf-grade female wistar Rats (6 weeks old) were obtained from the experimental Animals center of the third Military Medical university (chongqing, china).']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 23, 'Animals'), ('CHEBI_16412', 'lipopolysaccharide', 42, 'lipopolysaccharide'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 102, 'rats'), ('NCBITaxon_33208', 'Metazoa', 157, 'Animals'), ('UBERON_0006670', 'central tendon of diaphragm', 185, 'Military Medical')]
PMC4263713	12/2014	S49-PMC4263713	['for the Lps challenge, half of the 6-week-old pups in each group were randomly selected and injected Intraperitoneally with 3 mg/kg of Lps from E. Coli o111:b4; the other half of the pups were injected with an equal volume of pbs as the control.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 8, 'LPS'), ('UBERON_0000007', 'pituitary gland', 101, 'intraperitoneally'), ('CHEBI_16412', 'lipopolysaccharide', 135, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 144, 'E. coli')]
PMC4263713	12/2014	S97-PMC4263713	['following supplementation, the Serum Retinol levels of the 6-week-old Rats were significantly higher in the Rats in the vasp, vas1, vas2 and vas3 groups than in the Rats in the vad group with or without Lps challenge (fig.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 31, 'serum'), ('CHEBI_26536', 'retinoic acid', 37, 'retinol'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 70, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 108, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 165, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 203, 'LPS')]
PMC4263713	12/2014	S101-PMC4263713	['after the data from the Lps and the Lps-null treatment were combined, the Retinol levels were significantly higher in the Rats in the four vas groups (vasp, vas1, vas2 and vas3) than in the Rats in the vad group ( p<0.001;fig.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 24, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 36, 'LPS'), ('CHEBI_26536', 'retinoic acid', 74, 'retinol'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 122, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 190, 'rats')]
PMC4263713	12/2014	S103-PMC4263713	['the Serum Retinol levels were significantly lower in the Lps-challenged Rats than in the Rats in the combined Lps-null treatment group ( p<0.001;fig.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_26536', 'retinoic acid', 10, 'retinol'), ('CHEBI_16412', 'lipopolysaccharide', 57, 'LPS'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 72, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 89, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 110, 'LPS')]
PMC4263713	12/2014	S106-PMC4263713	['a) changes in the levels of Serum Retinol (µmol/l) in the Rats in the five groups (vad, vasp, vas1, vas2 and Vas3) in the presence or absence of Lps treatment (n\u200a=\u200a10 to 16) according to hplc analysis.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 28, 'serum'), ('CHEBI_26536', 'retinoic acid', 34, 'retinol'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 58, 'rats'), ('PR_000017279', 'testis-specific basic protein Y 1', 109, 'VAS3'), ('CHEBI_16412', 'lipopolysaccharide', 145, 'LPS')]
PMC4263713	12/2014	S107-PMC4263713	['b) vas, independent of the Lps challenge, significantly increased the Serum Retinol concentrations (µmol/l) of the Rats in the four combined vas groups.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 27, 'LPS'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_26536', 'retinoic acid', 76, 'retinol'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 115, 'rats')]
PMC4263713	12/2014	S109-PMC4263713	['d) changes in siga in the Intestinal Stool of the Rats in the five groups (vad, vasp, vas1, vas2 and vas3) with or without Lps challenge (n\u200a=\u200a5).']	N/A	N/A	[('UBERON_0000160', 'intestine', 26, 'intestinal'), ('UBERON_0001988', 'feces', 37, 'stool'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 50, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 123, 'LPS')]
PMC4263713	12/2014	S112-PMC4263713	['vitamin a supplementation enhanced Intestinal Iga secretion following Lipopolysaccharide challenge\nsiga participates in the Intestinal Innate Immune Response to protect the Epithelium from enteric pathogens and Toxins.fig.']	N/A	N/A	[('UBERON_0000160', 'intestine', 35, 'intestinal'), ('GO_0071746', 'IgA immunoglobulin complex, circulating', 46, 'IgA'), ('CHEBI_16412', 'lipopolysaccharide', 70, 'lipopolysaccharide'), ('UBERON_0000160', 'intestine', 124, 'intestinal'), ('GO_0045087', 'innate immune response', 135, 'innate immune response'), ('UBERON_0002405', 'immune system', 142, 'immune'), ('UBERON_0000483', 'epithelium', 173, 'epithelium'), ('CHEBI_27026', 'toxin', 211, 'toxins')]
PMC4263713	12/2014	S121-PMC4263713	['Lps challenge led to a further increase in the percentage of Cd4+Cd25+T Lymphocytes in the Rats in the vad, vasp and vas1 groups.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('PR_000001204', 'C-C chemokine receptor type 8', 61, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 65, 'CD25'), ('CL_0000084', 'T cell', 70, 'T lymphocytes'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 91, 'rats')]
PMC4263713	12/2014	S122-PMC4263713	['the interaction between the va level and Lps challenge did not significantly affect the percentage of Cd4+Cd25+T Cells.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 41, 'LPS'), ('PR_000001204', 'C-C chemokine receptor type 8', 102, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 106, 'CD25'), ('CL_0000084', 'T cell', 111, 'T cells')]
PMC4263713	12/2014	S135-PMC4263713	['c) the Lps challenge significantly enhanced the number of Cd4+Cd25+T Cells after the five va treatments were combined.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 7, 'LPS'), ('PR_000001204', 'C-C chemokine receptor type 8', 58, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 62, 'CD25'), ('CL_0000084', 'T cell', 67, 'T cells')]
PMC4263713	12/2014	S138-PMC4263713	['f) exposure to Lps significantly reduced the number of Cd4+Cd8+T Lymphocytes after the five va treatments were combined.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 15, 'LPS'), ('PR_000001204', 'C-C chemokine receptor type 8', 55, 'CD4'), ('CL_0000820', 'B-1a B cell', 59, 'CD8 ...'), ('PR_000005170', 'CD37 molecule', 59, 'CD8'), ('CL_0000084', 'T cell', 63, 'T lymphocytes')]
PMC4263713	12/2014	S166-PMC4263713	['a) the effects of Vas and Lps treatment on the percentage of Cd11C+Dcs Cells in the pps of the Rats in the five groups.']	N/A	N/A	[('CHEBI_39035', 'TES', 18, 'VAS'), ('CHEBI_16412', 'lipopolysaccharide', 26, 'LPS'), ('PR_000001309', 'CD70 molecule', 61, 'CD11c'), ('CL_0000586', 'germ cell', 67, 'DCs cells'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 95, 'rats')]
PMC4263713	12/2014	S168-PMC4263713	['c) the effects of Vas and Lps treatment on the percentage of Cd4+Cd25+T Cells in the Pps of the Rats in the five groups.']	N/A	N/A	[('CHEBI_39035', 'TES', 18, 'VAS'), ('CHEBI_16412', 'lipopolysaccharide', 26, 'LPS'), ('PR_000001204', 'C-C chemokine receptor type 8', 61, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 65, 'CD25'), ('CL_0000084', 'T cell', 70, 'T cells'), ('UBERON_0004302', 'proximal phalanx', 85, 'PPs'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 96, 'rats')]
PMC4263713	12/2014	S179-PMC4263713	['furthermore, the Lps challenge, which was independent of the va effect, significantly elevated the Cd8+Iels counts ( p<0.01;fig.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 17, 'LPS'), ('PR_000005170', 'CD37 molecule', 99, 'CD8'), ('CL_0002082', 'type II cell of adrenal medulla', 103, 'IELs')]
PMC4263713	12/2014	S183-PMC4263713	['the numbers of Cd8+Tcrγδ+Iels were significantly lower in the Rats in the vad+Lps group compared with the Rats in the vad Lps-null group ( p<0.001).']	N/A	N/A	[('PR_000005170', 'CD37 molecule', 15, 'CD8'), ('PR_000016190', 'trichohyalin-like protein 1', 19, 'TCRγδ'), ('CL_0002082', 'type II cell of adrenal medulla', 25, 'IELs'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 62, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 78, 'LPS'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 106, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 122, 'LPS')]
PMC4263713	12/2014	S190-PMC4263713	['d) the percentages of Cd8+Tcrγδ+Iels were significantly decreased in the Rats in the four Vas groups independent of exposure to Lps (n\u200a=\u200a8 to 10).']	N/A	N/A	[('PR_000005170', 'CD37 molecule', 22, 'CD8'), ('PR_000016190', 'trichohyalin-like protein 1', 26, 'TCRγδ'), ('CL_0002082', 'type II cell of adrenal medulla', 32, 'IELs'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 73, 'rats'), ('CHEBI_39035', 'TES', 90, 'VAS'), ('CHEBI_16412', 'lipopolysaccharide', 128, 'LPS')]
PMC4263713	12/2014	S195-PMC4263713	['7showed that the level of pigr mrna Expression was significantly higher in the vas1 Rats compared with the vad Rats in the presence of Lps ( p<0.001).']	N/A	N/A	[('GO_0010467', 'gene expression', 36, 'expression'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 84, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 111, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 135, 'LPS')]
PMC4263713	12/2014	S196-PMC4263713	['moreover, the mrna level of pigr was markedly induced in the Lps-challenged vas1 Rats ( p<0.001) compared with the Lps-null treatment group.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 61, 'LPS'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 81, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 115, 'LPS')]
PMC4263713	12/2014	S199-PMC4263713	['the changes in pigr mrna Expression levels in the Intestine were determined in both the vas1 and vad Rats with or without Lps challenge using real-time pcr (n\u200a=\u200a8).']	N/A	N/A	[('GO_0010467', 'gene expression', 25, 'expression'), ('UBERON_0000160', 'intestine', 50, 'intestine'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 101, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 122, 'LPS')]
PMC4263713	12/2014	S211-PMC4263713	['Lps challenge causes infection responses that decrease Serum Retinol levels[26].']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_26536', 'retinoic acid', 61, 'retinol')]
PMC4263713	12/2014	S251-PMC4263713	['the Lps challenge also increased the number of Cd8+Iels (fig.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 4, 'LPS'), ('PR_000005170', 'CD37 molecule', 47, 'CD8'), ('CL_0002082', 'type II cell of adrenal medulla', 51, 'IELs')]
PMC4263713	12/2014	S257-PMC4263713	['an Intraperitoneal injection of Lps induced a significant recruitment of Tcrγδ T Lymphocytes to the Peritoneal Cavity, which led to a decrease in the number of iels[37].']	N/A	N/A	[('UBERON_2001932', 'sensory canal tubular ossicle', 3, 'intraperitoneal'), ('CHEBI_16412', 'lipopolysaccharide', 32, 'LPS'), ('CL_0000805', 'immature single positive thymocyte', 73, 'TCRγδ T lymphocytes'), ('PR_000016190', 'trichohyalin-like protein 1', 73, 'TCRγδ'), ('UBERON_0001179', 'peritoneal cavity', 100, 'peritoneal cavity')]
PMC4277409	12/2014	S8-PMC4277409	['the Gsk3 Inhibitor Chir99021 significantly reduced the Gene Expression and secretion of the pro-inflammatory cytokines Tnf-Α, Il-1Β and Il-6; the pro-inflammatory chemokines Il-8 and Mcp-1; and the adhesion Molecules Icam-1 and Vcam-1 in Tissues stimulated with Lps or il-1β.']	N/A	N/A	[('CHEBI_86624', 'G b1-G', 4, 'GSK3'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 4, 'GSK3'), ('CHEBI_35222', 'inhibitor', 9, 'inhibitor'), ('CHEBI_64066', 'CGP 78608(1+)', 19, 'CHIR99021'), ('GO_0010467', 'gene expression', 55, 'gene expression'), ('SO_0000704', 'gene', 55, 'gene'), ('PR_000000134', 'tumor necrosis factor alpha', 119, 'TNF-α'), ('PR_000001383', 'interleukin-22', 126, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 136, 'IL-6'), ('PR_000001470', 'interleukin-28B', 174, 'IL-8'), ('PR_000010439', 'myeloid leukemia factor 1', 183, 'MCP-1'), ('CHEBI_36357', 'polyatomic entity', 207, 'molecules'), ('PR_000001367', 'interleukin-12 receptor subunit beta-1', 217, 'ICAM-1'), ('PR_000001970', 'vascular cell adhesion protein 1', 228, 'VCAM-1'), ('UBERON_0000479', 'tissue', 238, 'tissues'), ('CHEBI_16412', 'lipopolysaccharide', 262, 'LPS')]
PMC4277409	12/2014	S17-PMC4277409	['for example, the Tlr4 ligand bacterial Lipopolysaccharide (Lps) from the gram-negative Intestinal microbiota induces features of Metabolic diseases such as inflammation and Insulin resistance[23].']	N/A	N/A	[('PR_000001155', 'Toll-like receptor 4', 17, 'TLR4'), ('CHEBI_16412', 'lipopolysaccharide', 39, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 59, 'LPS'), ('UBERON_0000160', 'intestine', 87, 'intestinal'), ('GO_0008152', 'metabolic process', 129, 'metabolic'), ('PR_000045358', 'insulin family protein', 173, 'insulin')]
PMC4277409	12/2014	S54-PMC4277409	['Tissues were incubated in the absence or presence of 10 µm Chir99021 (selleck chemicals; houston, tx, usa) for 60 min before the addition of 10 µg/ml Lps (derived from escherichia coli 026:b6; sigma-aldrich, st. louis, mo, usa) or 1 ng/ml Il-1Β (peprotech; rocky hill, nj, usa) for 20 h. for Adipose Tissue, additional explants were performed using another Gsk3 Inhibitor sb216763 (selleck chemicals; houston, tx, usa).']	N/A	N/A	[('UBERON_0000479', 'tissue', 0, 'Tissues'), ('CHEBI_64066', 'CGP 78608(1+)', 59, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 150, 'LPS'), ('PR_000001383', 'interleukin-22', 239, 'IL-1β'), ('UBERON_0001013', 'adipose tissue', 292, 'adipose tissue'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 357, 'GSK3'), ('CHEBI_35222', 'inhibitor', 362, 'inhibitor')]
PMC4277409	12/2014	S55-PMC4277409	['for these studies, Adipose Tissue was incubated in the absence or presence of 20 µm Sb216763 for 60 min before the addition of 10 µg/ml Lps for 20 h. after final incubation, Tissue and media were collected separately and stored at −80°c for further analysis as detailed below.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 19, 'adipose tissue'), ('CHEBI_8978', 'SB 221284', 84, 'SB216763'), ('CHEBI_16412', 'lipopolysaccharide', 136, 'LPS'), ('UBERON_0000479', 'tissue', 174, 'tissue')]
PMC4277409	12/2014	S73-PMC4277409	['for the explant studies, there was a large variability in the response to Lps or Il-1Β which is normal for Tissues derived from different patients.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 74, 'LPS'), ('PR_000001383', 'interleukin-22', 81, 'IL-1β'), ('UBERON_0000479', 'tissue', 107, 'tissues')]
PMC4277409	12/2014	S74-PMC4277409	['thus, fold change was calculated relative to Lps or Il-1Β, which was set at 1.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 45, 'LPS'), ('PR_000001383', 'interleukin-22', 52, 'IL-1β')]
PMC4277409	12/2014	S98-PMC4277409	['representative western blot from 3 ngt and 3 diet-Controlled gdm patients is also shown.10.1371/journal.pone.0115854.g003\n\ncaption (fig): figure 3\neffect of Gsk3 Inhibitor Chir99021 on Lps-induced pro-inflammatory cytokines in Adipose Tissue.']	N/A	N/A	[('GO_0065007', 'biological regulation', 50, 'controlled'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 157, 'GSK3'), ('CHEBI_35222', 'inhibitor', 162, 'inhibitor'), ('CHEBI_64066', 'CGP 78608(1+)', 172, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 185, 'LPS'), ('UBERON_0001013', 'adipose tissue', 227, 'adipose tissue')]
PMC4277409	12/2014	S100-PMC4277409	['( b–g ) Human Omental Adipose Tissue was incubated with 10 µg/ml Lps in the absence or presence of 10 µm Chir99021 (chir) for 20 h (n\u200a=\u200a6 patients).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 8, 'Human'), ('UBERON_0001431', 'distal carpal bone 2', 14, 'omental adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 65, 'LPS'), ('CHEBI_64066', 'CGP 78608(1+)', 105, 'CHIR99021')]
PMC4277409	12/2014	S102-PMC4277409	['Gene Expression was normalised to gapdh mrna Expression and the fold change was calculated relative to Lps.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Gene expression'), ('SO_0000704', 'gene', 0, 'Gene'), ('GO_0010467', 'gene expression', 45, 'expression'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC4277409	12/2014	S104-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S107-PMC4277409	['* p<0.05 vs. Lps (one-way anova).10.1371/journal.pone.0115854.g004\n\ncaption (fig): figure 4\neffect of Gsk3 Inhibitor Chir99021 on Lps-induced pro-inflammatory cytokines in Skeletal muscle.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_77828', "guanosine 3',5'-bis(diphosphate)(5-)", 102, 'GSK3 inhibitor'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 102, 'GSK3'), ('CHEBI_64066', 'CGP 78608(1+)', 117, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 130, 'LPS'), ('UBERON_0004288', 'skeleton', 172, 'skeletal')]
PMC4277409	12/2014	S108-PMC4277409	['Human Skeletal muscle was incubated with 10 µg/ml Lps in the absence or presence of 10 µm Chir99021 (chir) for 20 h (n\u200a=\u200a6 patients).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0004288', 'skeleton', 6, 'skeletal'), ('CHEBI_16412', 'lipopolysaccharide', 50, 'LPS'), ('CHEBI_64066', 'CGP 78608(1+)', 90, 'CHIR99021')]
PMC4277409	12/2014	S110-PMC4277409	['Gene Expression was normalised to gapdh mrna Expression and the fold change was calculated relative to Lps.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Gene expression'), ('SO_0000704', 'gene', 0, 'Gene'), ('GO_0010467', 'gene expression', 45, 'expression'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC4277409	12/2014	S112-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S115-PMC4277409	['* p<0.05 vs. Lps (one-way anova).10.1371/journal.pone.0115854.g005\n\ncaption (fig): figure 5\neffect of Gsk3 Inhibitor Chir99021 on Il-1Β-induced pro-inflammatory cytokine Il-6 in Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_77828', "guanosine 3',5'-bis(diphosphate)(5-)", 102, 'GSK3 inhibitor'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 102, 'GSK3'), ('CHEBI_64066', 'CGP 78608(1+)', 117, 'CHIR99021'), ('PR_000001383', 'interleukin-22', 130, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 170, 'IL-6'), ('UBERON_0001013', 'adipose tissue', 178, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 197, 'skeletal')]
PMC4277409	12/2014	S123-PMC4277409	['* p<0.05 vs. Il-1Β (one-way anova).10.1371/journal.pone.0115854.g006\n\ncaption (fig): figure 6\neffect of Gsk3 Inhibitor Chir99021 on Lps-induced pro-inflammatory chemokines in Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('PR_000001383', 'interleukin-22', 13, 'IL-1β'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 104, 'GSK3'), ('CHEBI_35222', 'inhibitor', 109, 'inhibitor'), ('CHEBI_64066', 'CGP 78608(1+)', 119, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 132, 'LPS'), ('UBERON_0001013', 'adipose tissue', 175, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 194, 'skeletal')]
PMC4277409	12/2014	S124-PMC4277409	['Human ( a–d ) Omental Adipose Tissue and ( e–h ) Skeletal muscle were incubated with 10 µg/ml Lps in the absence or presence of 10 µm Chir99021 (chir) for 20 h (n\u200a=\u200a6 patients).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0001431', 'distal carpal bone 2', 14, 'omental adipose tissue'), ('UBERON_0004288', 'skeleton', 49, 'skeletal'), ('CHEBI_16412', 'lipopolysaccharide', 94, 'LPS'), ('CHEBI_64066', 'CGP 78608(1+)', 134, 'CHIR99021')]
PMC4277409	12/2014	S126-PMC4277409	['Gene Expression was normalised to gapdh mrna Expression and the fold change was calculated relative to Lps.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Gene expression'), ('SO_0000704', 'gene', 0, 'Gene'), ('GO_0010467', 'gene expression', 45, 'expression'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC4277409	12/2014	S128-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S131-PMC4277409	['* p<0.05 vs. Lps (one-way anova).10.1371/journal.pone.0115854.g007\n\ncaption (fig): figure 7\neffect of Gsk3 Inhibitor Chir99021 on Il-1Β induced pro-inflammatory chemokines in Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_77828', "guanosine 3',5'-bis(diphosphate)(5-)", 102, 'GSK3 inhibitor'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 102, 'GSK3'), ('CHEBI_64066', 'CGP 78608(1+)', 117, 'CHIR99021'), ('PR_000001383', 'interleukin-22', 130, 'IL-1β'), ('UBERON_0001013', 'adipose tissue', 175, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 194, 'skeletal')]
PMC4277409	12/2014	S139-PMC4277409	['* p<0.05 vs. Il-1Β (one-way anova).10.1371/journal.pone.0115854.g008\n\ncaption (fig): figure 8\neffect of Gsk3 Inhibitor Chir99021 on Lps-induced adhesion Molecules in Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('PR_000001383', 'interleukin-22', 13, 'IL-1β'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 104, 'GSK3'), ('CHEBI_35222', 'inhibitor', 109, 'inhibitor'), ('CHEBI_64066', 'CGP 78608(1+)', 119, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 132, 'LPS'), ('CHEBI_36357', 'polyatomic entity', 153, 'molecules'), ('UBERON_0001013', 'adipose tissue', 166, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 185, 'skeletal')]
PMC4277409	12/2014	S140-PMC4277409	['Human ( a–d ) Omental Adipose Tissue and ( e–h ) Skeletal muscle were incubated with 10 µg/ml Lps in the absence or presence of 10 µm Chir99021 (chir) for 20 h (n\u200a=\u200a6 patients).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0001431', 'distal carpal bone 2', 14, 'omental adipose tissue'), ('UBERON_0004288', 'skeleton', 49, 'skeletal'), ('CHEBI_16412', 'lipopolysaccharide', 94, 'LPS'), ('CHEBI_64066', 'CGP 78608(1+)', 134, 'CHIR99021')]
PMC4277409	12/2014	S142-PMC4277409	['Gene Expression was normalised to gapdh mrna Expression and the fold change was calculated relative to Lps.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Gene expression'), ('SO_0000704', 'gene', 0, 'Gene'), ('GO_0010467', 'gene expression', 45, 'expression'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC4277409	12/2014	S144-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S147-PMC4277409	['* p<0.05 vs. Lps (one-way anova).10.1371/journal.pone.0115854.g009\n\ncaption (fig): figure 9\neffect of Gsk3 Inhibitor Chir99021 on Il-1Β-induced adhesion Molecules in Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_77828', "guanosine 3',5'-bis(diphosphate)(5-)", 102, 'GSK3 inhibitor'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 102, 'GSK3'), ('CHEBI_64066', 'CGP 78608(1+)', 117, 'CHIR99021'), ('PR_000001383', 'interleukin-22', 130, 'IL-1β'), ('CHEBI_36357', 'polyatomic entity', 153, 'molecules'), ('UBERON_0001013', 'adipose tissue', 166, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 185, 'skeletal')]
PMC4277409	12/2014	S177-PMC4277409	['for these studies, inflammation was induced by the Tlr4 ligand bacterial endotoxin Lps and the pro-inflammatory cytokine Il-1Β.']	N/A	N/A	[('PR_000001155', 'Toll-like receptor 4', 51, 'TLR4'), ('CHEBI_16412', 'lipopolysaccharide', 83, 'LPS'), ('PR_000001383', 'interleukin-22', 121, 'IL-1β')]
PMC4277409	12/2014	S178-PMC4277409	['for Lps treatment, the data for Adipose Tissue and Skeletal muscle are depicted infigs.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 4, 'LPS'), ('UBERON_0001013', 'adipose tissue', 32, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 51, 'skeletal')]
PMC4277409	12/2014	S181-PMC4277409	['treatment with Lps induced a significant increase in Tnf-Α, Il-1Β and Il-6 mrna Expression and secretion in both Adipose Tissue and Skeletal muscle (figs.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 15, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 53, 'TNF-α'), ('PR_000001383', 'interleukin-22', 60, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 70, 'IL-6'), ('GO_0010467', 'gene expression', 80, 'expression'), ('UBERON_0001013', 'adipose tissue', 113, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 132, 'skeletal')]
PMC4277409	12/2014	S183-PMC4277409	['Chir99021 significantly decreased Lps-induced Tnf-Α, Il-1Β and Il-6 mrna Expression and secretion.']	N/A	N/A	[('CHEBI_64066', 'CGP 78608(1+)', 0, 'CHIR99021'), ('CHEBI_16412', 'lipopolysaccharide', 34, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 46, 'TNF-α'), ('PR_000001383', 'interleukin-22', 53, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 63, 'IL-6'), ('GO_0010467', 'gene expression', 73, 'expression')]
PMC4277409	12/2014	S191-PMC4277409	['6e–h), Lps induced a significant increase in Il-8 and Mcp-1 mrna Expression and secretion.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 7, 'LPS'), ('PR_000001470', 'interleukin-28B', 45, 'IL-8'), ('PR_000010439', 'myeloid leukemia factor 1', 54, 'MCP-1'), ('GO_0010467', 'gene expression', 65, 'expression')]
PMC4277409	12/2014	S192-PMC4277409	['in the presence of Chir99021, the increase in Chemokine Expression and Release induced by Lps was significantly attenuated.']	N/A	N/A	[('CHEBI_64066', 'CGP 78608(1+)', 19, 'CHIR99021'), ('GO_0019221', 'cytokine-mediated signaling pathway', 46, 'chemokine expression ... release'), ('CHEBI_16412', 'lipopolysaccharide', 90, 'LPS')]
PMC4277409	12/2014	S205-PMC4277409	['the data for Lps are presented are presented infig.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S210-PMC4277409	['8e–h;9e–h) with Lps or Il-1Β induced a significant increase in Vcam-1 and Icam-1 mrna Expression.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 16, 'LPS'), ('PR_000001383', 'interleukin-22', 23, 'IL-1β'), ('PR_000001970', 'vascular cell adhesion protein 1', 63, 'VCAM-1'), ('PR_000001367', 'interleukin-12 receptor subunit beta-1', 74, 'ICAM-1'), ('GO_0010467', 'gene expression', 86, 'expression')]
PMC4277409	12/2014	S219-PMC4277409	['the effect of sb216763 on Lps-induced inflammation is presented infig.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 26, 'LPS')]
PMC4277409	12/2014	S221-PMC4277409	['sb216763 significantly decreased Lps-induced mrna Expression and secretion of pro-inflammatory cytokines (Tnf-Α, Il-1Β and Il-6) and chemokines (Il-8 and Mcp-1).10.1371/journal.pone.0115854.g010\n\ncaption (fig): figure 10\neffect of Gsk3 inhibitor sb216763 on Lps-induced pro-inflammatory cytokines and chemokines in Adipose Tissue.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 33, 'LPS'), ('GO_0010467', 'gene expression', 50, 'expression'), ('PR_000000134', 'tumor necrosis factor alpha', 106, 'TNF-α'), ('PR_000001383', 'interleukin-22', 113, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 123, 'IL-6'), ('PR_000001470', 'interleukin-28B', 145, 'IL-8'), ('PR_000010439', 'myeloid leukemia factor 1', 154, 'MCP-1'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 231, 'GSK3'), ('CHEBI_16412', 'lipopolysaccharide', 258, 'LPS'), ('UBERON_0001013', 'adipose tissue', 315, 'adipose tissue')]
PMC4277409	12/2014	S222-PMC4277409	['Human Omental Adipose Tissue was incubated with 10 µg/ml Lps in the absence or presence of 20 µm Sb216763 (sb) for 20 h (n\u200a=\u200a5 patients).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0001431', 'distal carpal bone 2', 6, 'omental adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 57, 'LPS'), ('CHEBI_8978', 'SB 221284', 97, 'SB216763')]
PMC4277409	12/2014	S224-PMC4277409	['Gene Expression was normalised to gapdh mrna Expression and the fold change was calculated relative to Lps.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Gene expression'), ('SO_0000704', 'gene', 0, 'Gene'), ('GO_0010467', 'gene expression', 45, 'expression'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC4277409	12/2014	S226-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S229-PMC4277409	['* p<0.05 vs. Lps (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4277409	12/2014	S231-PMC4277409	['chemical inhibition of Gsk3 with the Synthetic Compound Chir99021 could efficiently prevent the Expression and release of pro-Inflammatory Mediators in Omental Adipose Tissue and Skeletal muscle that were stimulated with Tlr4 ligand and bacterial product Lps and the pro-inflammatory cytokine Il-1Β.']	N/A	N/A	[('PR_000008288', 'glycogen synthase kinase-3 beta', 23, 'GSK3'), ('CHEBI_35858', '1-benzothiophene', 37, 'synthetic'), ('CHEBI_36357', 'polyatomic entity', 47, 'compound'), ('CHEBI_64066', 'CGP 78608(1+)', 56, 'CHIR99021'), ('GO_0010467', 'gene expression', 96, 'expression'), ('CHEBI_64664', '(2-nitrophenyl)azo group', 125, '-inflammatory mediators'), ('UBERON_0001431', 'distal carpal bone 2', 152, 'omental adipose tissue'), ('UBERON_0004288', 'skeleton', 179, 'skeletal'), ('PR_000001155', 'Toll-like receptor 4', 221, 'TLR4'), ('CHEBI_16412', 'lipopolysaccharide', 255, 'LPS'), ('PR_000001383', 'interleukin-22', 293, 'IL-1β')]
PMC4277409	12/2014	S256-PMC4277409	['indeed, in vitro , bacterial endotoxin Lps induces the Expression of pro-inflammatory cytokines in Adipose Tissue and Skeletal muscle from Pregnant women[13],[15].']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 39, 'LPS'), ('GO_0010467', 'gene expression', 55, 'expression'), ('UBERON_0001013', 'adipose tissue', 99, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 118, 'skeletal'), ('GO_0007565', 'female pregnancy', 139, 'pregnant')]
PMC4277409	12/2014	S260-PMC4277409	['Lps) induced the Expression and secretion of pro-inflammatory cytokines from Human Pregnant Adipose Tissue and Skeletal muscle.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('GO_0010467', 'gene expression', 17, 'expression'), ('NCBITaxon_9606', 'Homo sapiens', 77, 'human'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('UBERON_0001013', 'adipose tissue', 92, 'adipose tissue'), ('UBERON_0004288', 'skeleton', 111, 'skeletal')]
PMC4277409	12/2014	S270-PMC4277409	['Icam and Vcam, which are constitutively Expressed in a few cell types, are induced by a various pro-inflammatory stimuli, including Il-1Β and Lps[50].']	N/A	N/A	[('PR_000001868', 'interleukin-6 receptor subunit beta', 0, 'ICAM'), ('PR_000017279', 'testis-specific basic protein Y 1', 9, 'VCAM'), ('GO_0010467', 'gene expression', 40, 'expressed'), ('PR_000001383', 'interleukin-22', 132, 'IL-1β'), ('CHEBI_16412', 'lipopolysaccharide', 142, 'LPS')]
PMC4277409	12/2014	S294-PMC4277409	['in this study, Lps and Il-1Β were used to mimic a gdm environment.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 15, 'LPS'), ('PR_000001383', 'interleukin-22', 23, 'IL-1β')]
PMC4277409	12/2014	S299-PMC4277409	['induction of the Gene Expression and secretion of pro-inflammatory cytokines and chemokines, and adhesion Molecules in the presence of Lps or Il-1Β were significantly decreased by the Gsk3 Inhibitor Chir99021.']	N/A	N/A	[('GO_0010467', 'gene expression', 17, 'gene expression'), ('SO_0000704', 'gene', 17, 'gene'), ('CHEBI_36357', 'polyatomic entity', 106, 'molecules'), ('CHEBI_16412', 'lipopolysaccharide', 135, 'LPS'), ('PR_000001383', 'interleukin-22', 142, 'IL-1β'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 184, 'GSK3'), ('CHEBI_35222', 'inhibitor', 189, 'inhibitor'), ('CHEBI_64066', 'CGP 78608(1+)', 199, 'CHIR99021')]
PMC4292443	1/2015	S27-PMC4292443	['however, neonatal overfeeding also causes significant and substantial peripheral and central inflammation, including a pro-inflammatory profile in systemic Tissue and the Hypothalamus, as well as exacerbated pro-inflammatory response to a Neuroimmune challenge with bacterial mimetic Lipopolysaccharide (Lps) (tapia-gonzalez et al.,2011; clarke et al.,2012; ye et al.,2012; ziko et al.,2014).']	N/A	N/A	[('UBERON_0000479', 'tissue', 156, 'tissue'), ('UBERON_0001898', 'hypothalamus', 171, 'hypothalamus'), ('UBERON_0001049', 'neural tube', 239, 'neuroimmune'), ('CHEBI_16412', 'lipopolysaccharide', 284, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 304, 'LPS')]
PMC4292443	1/2015	S34-PMC4292443	['Lps.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS')]
PMC4292443	1/2015	S55-PMC4292443	['two days later, i.e., after 4 or 22 days high fat diet (or Chow), the pairs of Rats were then randomly allocated into the saline or Lps group.']	N/A	N/A	[('CHEBI_33290', 'food', 59, 'chow'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 79, 'rats'), ('CHEBI_16412', 'lipopolysaccharide', 132, 'LPS')]
PMC4292443	1/2015	S57-PMC4292443	['injection of Lps ( E. Coli , serotype 026:b6; l-3755; sigma, st louis, mo, usa; 100 μg/kg), or Pyrogen-free saline.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 19, 'E. coli'), ('CHEBI_26407', 'pyrans', 95, 'pyrogen')]
PMC4292443	1/2015	S176-PMC4292443	['Lps significantly increased Liver Il-1Α, Il-1Β, Il-6, and tnfα across the groups, but there were no significant differences with the post - hoc tests except in Il-1Α cl after 3d high fat diet.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('UBERON_0002107', 'liver', 28, 'liver'), ('PR_000001388', 'interleukin-32', 34, 'IL-1α'), ('PR_000001383', 'interleukin-22', 41, 'IL-1β'), ('PR_000001470', 'interleukin-28B', 48, 'IL-6'), ('PR_000001388', 'interleukin-32', 160, 'IL-1α')]
PMC4292443	1/2015	S216-PMC4292443	['caption (fig): figure 7\n\neffects of neonatal overfeeding on Neuronal activation in response to Lps .']	N/A	N/A	[('CL_0000540', 'neuron', 60, 'neuronal'), ('CHEBI_16412', 'lipopolysaccharide', 95, 'LPS')]
PMC4292443	1/2015	S217-PMC4292443	['Neuronal activation in the medial parvocellular (Mp) (a,b) and magnocellular (mg) (c,d) Paraventricular Nucleus Of the Hypothalamus (Pvn), the Ventral Bed Nucleus Of the Stria Terminalis (Vbnst) (e,f) , the Ventromedial Preoptic Area (Vmpoa) (g,h) and the Vascular Organ Of the Laminar Terminalis (Ovlt) (i,j) with Lps after 3 day (3d) and 3 week (3w) high fat diet or Chow (Ch) in male (a,c,e,g,i) and female (b,d,f,h,j) Adult Rats that were raised in control (cl) and small (sl) litters.']	N/A	N/A	[('CL_0000540', 'neuron', 0, 'Neuronal'), ('UBERON_2002207', 'medial motor nucleus of vagal nerve', 49, 'mp'), ('UBERON_0001930', 'paraventricular nucleus of hypothalamus', 88, 'paraventricular nucleus of ... hypothalamus'), ('UBERON_0009910', 'posterior lateral plate mesoderm', 133, 'PVN'), ('UBERON_0011179', 'transverse nucleus of stria terminalis', 143, 'ventral bed nucleus of ... stria terminalis'), ('UBERON_0001983', 'crypt of Lieberkuhn', 188, 'vBNST'), ('UBERON_0002594', 'dentatothalamic tract', 207, 'ventromedial preoptic area'), ('UBERON_0007377', 'stratum compactum of dermis', 235, 'VMPOA'), ('UBERON_0000116', 'lung saccule', 256, 'vascular'), ('UBERON_0001533', 'subclavian artery', 265, 'organ of ... laminar terminalis'), ('UBERON_0002689', 'supraoptic crest', 298, 'OVLT'), ('CHEBI_16412', 'lipopolysaccharide', 315, 'LPS'), ('CHEBI_33290', 'food', 369, 'chow'), ('CHEBI_17996', 'chloride', 375, 'CH'), ('UBERON_0007023', 'adult organism', 422, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 428, 'rats')]
PMC4292443	1/2015	S237-PMC4292443	['in the ovlt there were no relevant differences with post - hoc tests except that in females there were more Fos-positive cells with Lps after 3w high fat diet in cl Rats than in sl.']	N/A	N/A	[('PR_000007705', 'galactoside alpha-(1,2)-fucosyltransferase 2', 108, 'Fos'), ('CHEBI_16412', 'lipopolysaccharide', 132, 'LPS'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 165, 'rats')]
PMC4354412	3/2015	S29-PMC4354412	['the Epithelial Cells Of the Mammary Gland of Mice Express mcd14 (12), which acts as a co-receptor for the detection of bacterial Lipopolysaccharide (Lps) together with the Toll-Like Receptor 4 (Tlr4).']	N/A	N/A	[('CL_0002642', 'epithelial cell of esophageal cardiac gland', 4, 'epithelial cells of ... mammary gland'), ('UBERON_0000483', 'epithelium', 4, 'epithelial'), ('UBERON_0001911', 'mammary gland', 28, 'mammary gland'), ('NCBITaxon_10088', 'Mus <genus>', 45, 'mice'), ('GO_0010467', 'gene expression', 50, 'express'), ('CHEBI_16412', 'lipopolysaccharide', 129, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 149, 'LPS'), ('PR_000001156', 'Toll-like receptor 5', 172, 'Toll-like receptor 4'), ('PR_000001155', 'Toll-like receptor 4', 194, 'TLR4')]
PMC4354412	3/2015	S33-PMC4354412	['Fetal Iecs Express Tlr4 and are hyperresponsive to Lps (19).']	N/A	N/A	[('CL_0002062', 'type I pneumocyte', 0, 'Fetal IECs'), ('GO_0010467', 'gene expression', 11, 'express'), ('PR_000001155', 'Toll-like receptor 4', 19, 'TLR4'), ('CHEBI_16412', 'lipopolysaccharide', 51, 'LPS')]
PMC4354412	3/2015	S34-PMC4354412	['in Mice, Scd14 reduces inflammatory Responses by blocking circulating Lps thereby limiting the amount of Monocyte-bound Lps (20).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 3, 'mice'), ('PR_000002097', 'sodium channel protein type 11 subunit alpha', 9, 'sCD14'), ('GO_0060033', 'anatomical structure regression', 36, 'responses'), ('CHEBI_16412', 'lipopolysaccharide', 70, 'LPS'), ('CL_0000576', 'monocyte', 105, 'monocyte'), ('CHEBI_16412', 'lipopolysaccharide', 120, 'LPS')]
PMC4388824	4/2015	S6-PMC4388824	['Thapsigargin, an Er Stress activator, induced upregulated secretion of mature Il-1Α and Il-1Β in Human Omental Adipose Tissue explants primed with bacterial endotoxin Lps, the Viral dsrna analogue poly(I:c) or the pro-inflammatory cytokine Tnf-Α.']	N/A	N/A	[('PR_000001959', 'tumor necrosis factor receptor superfamily member 1B', 0, 'Thapsigargin'), ('GO_0044311', 'exoneme', 17, 'ER stress'), ('PR_000001388', 'interleukin-32', 78, 'IL-1α'), ('PR_000001383', 'interleukin-22', 88, 'IL-1β'), ('NCBITaxon_9606', 'Homo sapiens', 97, 'human'), ('UBERON_0001431', 'distal carpal bone 2', 103, 'omental adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 167, 'LPS'), ('NCBITaxon_1', 'root', 176, 'viral'), ('CHEBI_51686', 'haematoxylin', 202, 'I'), ('SO_0001434', 'cassette_pseudogene', 202, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 240, 'TNF-α')]
PMC4388824	4/2015	S55-PMC4388824	['Tissues were incubated in the absence or presence of 10 μg/ml Lps (derived from e .']	N/A	N/A	[('UBERON_0000479', 'tissue', 0, 'Tissues'), ('CHEBI_16412', 'lipopolysaccharide', 62, 'LPS')]
PMC4388824	4/2015	S57-PMC4388824	['additional experiments were also performed whereby Adipose Tissue was pre-treated with 20 μm of the Caspase-1 Inhibitor Ac-Yvad-Cho, 10 μm of the connexin/Pannexin-1 channel Blocker Carbenoxolone, or with two Anti-Diabetic Drugs, 25 μm Glibenclamide or 0.5 mm Metformin prior to the addition of Lps, Poly(I:c) or Tnf-Α.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 51, 'adipose tissue'), ('PR_000002310', 'caspase-10', 100, 'caspase-1'), ('CHEBI_35222', 'inhibitor', 110, 'inhibitor'), ('CHEBI_2787', 'Apovincamine', 120, 'Ac-YVAD-'), ('CHEBI_17883', 'hydrogen chloride', 128, 'CHO'), ('PR_000012528', 'Na(+)/H(+) exchange regulatory cofactor NHE-RF3', 155, 'pannexin-1'), ('CHEBI_35225', 'buffer', 174, 'blocker'), ('CHEBI_51687', 'chrysene', 182, 'carbenoxolone'), ('CHEBI_35829', 'arsenic(5+)', 209, 'anti-diabetic drugs'), ('CHEBI_5383', 'glimepiride', 236, 'glibenclamide'), ('CHEBI_6801', 'metformin', 260, 'metformin'), ('CHEBI_16412', 'lipopolysaccharide', 295, 'LPS'), ('CHEBI_37311', 'einsteinium molecular entity', 300, 'poly'), ('CHEBI_51686', 'haematoxylin', 305, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 313, 'TNF-α')]
PMC4388824	4/2015	S70-PMC4388824	['thus, fold change was calculated relative to Lps, poly(I:c) or Tnf-Α, which was set at 1.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 45, 'LPS'), ('CHEBI_51686', 'haematoxylin', 55, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 63, 'TNF-α')]
PMC4388824	4/2015	S106-PMC4388824	['Adipose Tissue was incubated in the absence or presence of (a-f) 10 μg/ml Lps (n = 6 patients), (g-l) 20 μg/ml Poly(I:c) (n = 6 patients), or (m-r) 10 ng/ml tnf-α.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 0, 'Adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 74, 'LPS'), ('CHEBI_37311', 'einsteinium molecular entity', 111, 'poly'), ('CHEBI_51686', 'haematoxylin', 116, 'I')]
PMC4388824	4/2015	S110-PMC4388824	['* p<0.05 vs. Lps (one way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS')]
PMC4388824	4/2015	S112-PMC4388824	['† p<0.05 vs. Tnf-Α (one-way anova).10.1371/journal.pone.0122633.g003\n\ncaption (fig): fig 3\nCaspase-1 Regulates thapsigargin-induced Il-1Α and Il-1Β secretion in Tissues primed with Lps, poly(I:c) or Tnf-Α.']	N/A	N/A	[('PR_000000134', 'tumor necrosis factor alpha', 13, 'TNF-α'), ('PR_000002319', 'catenin beta-1 isoform 1', 91, 'Caspase-1'), ('GO_0065007', 'biological regulation', 101, 'regulates'), ('PR_000001388', 'interleukin-32', 132, 'IL-1α'), ('PR_000001383', 'interleukin-22', 142, 'IL-1β'), ('UBERON_0000479', 'tissue', 161, 'tissues'), ('CHEBI_16412', 'lipopolysaccharide', 181, 'LPS'), ('CHEBI_51686', 'haematoxylin', 191, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 199, 'TNF-α')]
PMC4388824	4/2015	S113-PMC4388824	['Adipose Tissue was incubated in the absence or presence of 10 μm Ac-Yvad-Cho (yvad) for 60 min prior to the addition of (a-c) 10 μg/ml Lps, (d-f) 20 μg/ml Poly(I:c) or (g-i) 10 ng/ml Tnf-Α.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 0, 'Adipose tissue'), ('CHEBI_37527', 'acid', 65, 'Ac'), ('CHEBI_79374', 'ibho#22', 68, 'YVAD'), ('CHEBI_17883', 'hydrogen chloride', 73, 'CHO'), ('CHEBI_16412', 'lipopolysaccharide', 135, 'LPS'), ('CHEBI_37311', 'einsteinium molecular entity', 155, 'poly'), ('CHEBI_51686', 'haematoxylin', 160, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 183, 'TNF-α')]
PMC4388824	4/2015	S117-PMC4388824	['* p<0.05 vs. Lps (one way anova); ** p<0.05 vs. Lps + tg (one way anova); # p<0.05 vs. poly(i:c) (one-way anova); ## p<0.05 vs. poly(i:c) + tg (one-way anova); † p<0.05 vs. Tnf-Α (one-way anova); †† p<0.05 vs. Tnf-Α + tg (one-way anova).10.1371/journal.pone.0122633.g004\n\ncaption (fig): fig 4\nPannexin-1 Regulates thapsigargin-induced Il-1Β but not Il-1Α secretion in Tissues primed with Lps, poly(i:c) or Tnf-Α.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 173, 'TNF-α'), ('PR_000000134', 'tumor necrosis factor alpha', 210, 'TNF-α'), ('PR_000012429', 'protein PCOTH', 293, 'Pannexin-1'), ('GO_0065007', 'biological regulation', 304, 'regulates'), ('PR_000001383', 'interleukin-22', 335, 'IL-1β'), ('PR_000001388', 'interleukin-32', 349, 'IL-1α'), ('UBERON_0000479', 'tissue', 368, 'tissues'), ('CHEBI_16412', 'lipopolysaccharide', 388, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 406, 'TNF-α')]
PMC4388824	4/2015	S118-PMC4388824	['Adipose Tissue was incubated in the absence or presence of 10 μm Carbenoxolone (Carb) for 60 min prior to the addition of (a-c) 10 μg/ml Lps, (d-f) 20 μg/ml Poly(I:c) or (g-i) 10 ng/ml Tnf-Α.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 0, 'Adipose tissue'), ('CHEBI_51687', 'chrysene', 65, 'carbenoxolone'), ('CHEBI_82156', 'Chlorfensulphide', 80, 'Carb'), ('CHEBI_16412', 'lipopolysaccharide', 137, 'LPS'), ('CHEBI_37311', 'einsteinium molecular entity', 157, 'poly'), ('CHEBI_51686', 'haematoxylin', 162, 'I'), ('PR_000000134', 'tumor necrosis factor alpha', 185, 'TNF-α')]
PMC4388824	4/2015	S122-PMC4388824	['* p<0.05 vs. Lps (one way anova); ** p<0.05 vs. Lps + tg (one way anova); # p<0.05 vs. poly(i:c) (one-way anova); ## p<0.05 vs. poly(i:c) + tg (one-way anova); † p<0.05 vs. Tnf-Α (one-way anova); †† p<0.05 vs. Tnf-Α + tg (one-way anova).10.1371/journal.pone.0122633.g005\n\ncaption (fig): fig 5\nAnti-Diabetic Drugs inhibits thapsigargin-induced Il-1Α and Il-1Β secretion in Tissues primed with Lps, poly(i:c) or Tnf-Α.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 173, 'TNF-α'), ('PR_000000134', 'tumor necrosis factor alpha', 210, 'TNF-α'), ('CHEBI_35842', 'antirheumatic drug', 293, 'Anti-diabetic drugs'), ('PR_000001388', 'interleukin-32', 343, 'IL-1α'), ('PR_000001383', 'interleukin-22', 353, 'IL-1β'), ('UBERON_0000479', 'tissue', 372, 'tissues'), ('CHEBI_16412', 'lipopolysaccharide', 392, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 410, 'TNF-α')]
PMC4388824	4/2015	S123-PMC4388824	['Adipose Tissue was incubated in the absence or presence of 0.5 mm Metformin (metf) or 25 μm Glibenclamide (glib)for 60 min prior to the addition of (a-c) 10 μg/ml Lps, (d-f) 20 μg/ml Poly(I:C) or (g-i) 10 ng/ml Tnf-Α.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 0, 'Adipose tissue'), ('CHEBI_6801', 'metformin', 66, 'metformin'), ('CHEBI_5383', 'glimepiride', 92, 'glibenclamide'), ('CHEBI_16412', 'lipopolysaccharide', 163, 'LPS'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 183, 'poly(I:C'), ('PR_000000134', 'tumor necrosis factor alpha', 211, 'TNF-α')]
PMC4388824	4/2015	S127-PMC4388824	['* p<0.05 vs. Lps (one way anova); ** p<0.05 vs. Lps + tg (one way anova); # p<0.05 vs. poly(i:c) (one-way anova); ## p<0.05 vs. poly(i:c) + tg (one-way anova); † p<0.05 vs. Tnf-Α (one-way anova); †† p<0.05 vs. Tnf-Α + tg (one-way anova).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 48, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 173, 'TNF-α'), ('PR_000000134', 'tumor necrosis factor alpha', 210, 'TNF-α')]
PMC4388824	4/2015	S155-PMC4388824	['Lps induced a significant increase in both Il-1Α and Il-1Β mrna Expression (fig2aand2b) and secretion (fig2dand2e) in Adipose Tissue.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('PR_000001388', 'interleukin-32', 43, 'IL-1α'), ('PR_000001383', 'interleukin-22', 53, 'IL-1β'), ('GO_0010467', 'gene expression', 64, 'expression'), ('UBERON_0001013', 'adipose tissue', 118, 'adipose tissue')]
PMC4388824	4/2015	S158-PMC4388824	['as expected, Lps induced a significant increase in Il-6 mrna Expression (fig 2c) and release (fig 2f).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 13, 'LPS'), ('PR_000001470', 'interleukin-28B', 51, 'IL-6'), ('GO_0010467', 'gene expression', 61, 'expression')]
PMC4388824	4/2015	S164-PMC4388824	['in contrast to Lps and Poly(I:C) treatments, Tnf-Α increased Il-1Α and Il-1Β mrna Expression (fig2mand2n) but not secretion (fig2pand2q) in Pregnant Adipose Tissue.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 15, 'LPS'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 23, 'poly(I:C'), ('PR_000000134', 'tumor necrosis factor alpha', 45, 'TNF-α'), ('PR_000001388', 'interleukin-32', 61, 'IL-1α'), ('PR_000001383', 'interleukin-22', 71, 'IL-1β'), ('GO_0010467', 'gene expression', 82, 'expression'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('UBERON_0001013', 'adipose tissue', 149, 'adipose tissue')]
PMC4388824	4/2015	S170-PMC4388824	['pre-treatment with the specific Caspase-1 Inhibitor Ac-Yvad-Cho significantly attenuated Thapsigargin-induced Il-1Α and Il-1Β in Adipose Tissue primed with Lps (fig3aand3b), poly(i:c) (fig3dand3e) or Tnf-Α (fig3gand3h).']	N/A	N/A	[('PR_000002310', 'caspase-10', 32, 'caspase-1'), ('CHEBI_35222', 'inhibitor', 42, 'inhibitor'), ('CHEBI_60884', 'poly(N-n-propylacrylamide) polymer', 52, 'Ac-YVAD'), ('CHEBI_17883', 'hydrogen chloride', 60, 'CHO'), ('CHEBI_9516', 'thapsigargin', 89, 'thapsigargin'), ('PR_000001388', 'interleukin-32', 110, 'IL-1α'), ('PR_000001383', 'interleukin-22', 120, 'IL-1β'), ('UBERON_0001013', 'adipose tissue', 129, 'adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 156, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 200, 'TNF-α')]
PMC4388824	4/2015	S178-PMC4388824	['pre-treatment with Metformin or Glibenclamide significantly attenuated thapsigargin-enhanced Il-1Α and Il-1Β secretion in Adipose Tissue primed with Lps (fig5aand5b), poly(i:c) (fig5dand5e) or Tnf-Α (fig5gand5h).']	N/A	N/A	[('CHEBI_6801', 'metformin', 19, 'metformin'), ('CHEBI_5383', 'glimepiride', 32, 'glibenclamide'), ('PR_000001388', 'interleukin-32', 93, 'IL-1α'), ('PR_000001383', 'interleukin-22', 103, 'IL-1β'), ('UBERON_0001013', 'adipose tissue', 122, 'adipose tissue'), ('CHEBI_16412', 'lipopolysaccharide', 149, 'LPS'), ('PR_000000134', 'tumor necrosis factor alpha', 193, 'TNF-α')]
PMC4388824	4/2015	S183-PMC4388824	['furthermore, Anti-Diabetic Drugs Metformin and Glibenclamide also suppressed thapsigargin-induced Inflammasome Activation in Tissues primed with Lps, Poly(I:C) or tnf-Α.']	N/A	N/A	[('CHEBI_35829', 'arsenic(5+)', 13, 'anti-diabetic drugs'), ('CHEBI_6801', 'metformin', 33, 'metformin'), ('CHEBI_5383', 'glimepiride', 47, 'glibenclamide'), ('GO_0001954', 'positive regulation of cell-matrix adhesion', 98, 'inflammasome activation'), ('GO_0061702', 'inflammasome complex', 98, 'inflammasome'), ('UBERON_0000479', 'tissue', 125, 'tissues'), ('CHEBI_16412', 'lipopolysaccharide', 145, 'LPS'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 150, 'poly(I:C'), ('SO_0001434', 'cassette_pseudogene', 155, 'I'), ('PR_000006000', 'carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2', 167, 'α')]
PMC4388824	4/2015	S210-PMC4388824	['Lps, Poly(I:C) and Tnf-Α all induced Il-1Α and Il-1Β Gene transcription with minimal Il-1Α and il-1Β Cytokine Release.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 5, 'poly(I:C'), ('PR_000000134', 'tumor necrosis factor alpha', 19, 'TNF-α'), ('PR_000001388', 'interleukin-32', 37, 'IL-1α'), ('PR_000001383', 'interleukin-22', 47, 'IL-1β'), ('SO_0000704', 'gene', 53, 'gene'), ('PR_000001388', 'interleukin-32', 85, 'IL-1α'), ('PR_000000035', 'BMP receptor type-1A', 97, '-1β'), ('GO_0002002', 'regulation of angiotensin levels in blood', 101, 'cytokine release')]
PMC4388824	4/2015	S233-PMC4388824	['the first signal required is mediated by an exogenous stimuli, such as the tlr ligands Lps (Tlr4) and Poly(I:C) (Tlr3) and the pro-inflammatory cytokine Tnf-Α, triggering the Gene transcription of Il-1 and a modest Production Of mature Il-1.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 87, 'LPS'), ('PR_000001155', 'Toll-like receptor 4', 92, 'TLR4'), ('CHEBI_59159', 'beta-terpinene', 102, 'poly(I:'), ('SO_0001587', 'stop_gained', 102, 'poly(I:C'), ('PR_000001155', 'Toll-like receptor 4', 113, 'TLR3'), ('PR_000000134', 'tumor necrosis factor alpha', 153, 'TNF-α'), ('SO_0000704', 'gene', 175, 'gene'), ('PR_000001470', 'interleukin-28B', 197, 'IL-1'), ('GO_0000741', 'karyogamy', 215, 'production of ... IL-1'), ('PR_000001470', 'interleukin-28B', 236, 'IL-1')]
PMC4448820	5/2015	S209-PMC4448820	['○ in Humans, the Generation Of Tnf By Peripheral Blood Mononuclear Cells (Pbmcs) in response to Lps is reduced by short-term zinc deprivation.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 5, 'humans'), ('GO_0061728', 'GDP-mannose biosynthetic process from mannose', 17, 'generation of TNF by ... cells'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 31, 'TNF'), ('CL_0000111', 'peripheral neuron', 38, 'peripheral blood mononuclear cells'), ('UBERON_0012101', 'perinatal stage', 38, 'peripheral blood'), ('GO_0031097', 'medial cortex', 55, 'mononuclear'), ('CL_0002246', 'peripheral blood stem cell', 74, 'PBMCs'), ('CHEBI_16412', 'lipopolysaccharide', 96, 'LPS')]
PMC4448820	5/2015	S387-PMC4448820	['a greater association of Kdm6B/Jmjd3 to the cyp24a1 Promoter Gene and induction of cyp24a1 mrna occurs in response to Lps in Mouse Macrophages (217).']	N/A	N/A	[('PR_000009209', 'juxtaposed with another zinc finger protein 1', 25, 'KDM6B'), ('PR_000009211', 'lysine-specific demethylase 3A', 31, 'JMJD3'), ('SO_0000167', 'promoter', 52, 'promoter'), ('SO_0000704', 'gene', 61, 'gene'), ('CHEBI_16412', 'lipopolysaccharide', 118, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 125, 'mouse'), ('CL_0000235', 'macrophage', 131, 'macrophages')]
PMC4448820	5/2015	S829-PMC4448820	['● in sympathectomized Mice, Macrophage Stimulation with Lps results in increased Production Of Tnf (239,461).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 22, 'mice'), ('CL_0000235', 'macrophage', 28, 'macrophage'), ('GO_0042116', 'macrophage activation', 28, 'macrophage stimulation'), ('CHEBI_16412', 'lipopolysaccharide', 56, 'LPS'), ('GO_0034260', 'negative regulation of GTPase activity', 81, 'production of TNF'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 95, 'TNF')]
PMC4512131	8/2015	S184-PMC4512131	['b/f, bacteroidetes/firmicutes; c-section, cesarean section; gwg, Gestational weight gain; Lps, Lipopolysaccharide; Mirna, microrna; ncrna, Noncoding Rna.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 65, 'gestational'), ('CHEBI_16412', 'lipopolysaccharide', 90, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 95, 'lipopolysaccharide'), ('SO_0000276', 'miRNA', 115, 'miRNA'), ('SO_0001831', 'protein_hmm_match', 139, 'noncoding RNA')]
PMC4685088	12/2015	S163-PMC4685088	['for the chorioamnionitis Rodent models, the exposure to Lps is over a few days in the late canalicular/early Saccular stage of Lung Development.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 25, 'rodent'), ('CHEBI_16412', 'lipopolysaccharide', 56, 'LPS'), ('UBERON_0000116', 'lung saccule', 109, 'saccular'), ('GO_0030324', 'lung development', 127, 'lung development'), ('UBERON_0002048', 'lung', 127, 'lung')]
PMC4738402	11/2015	S41-PMC4738402	['total concentration of muscarinic receptors was determined as the specific binding of the non‐selective muscarinic receptor antagonist [3H]‐ N ‐Methylscopolamine ([3H]‐Nms; 2\xa0nm, specific radioactivity 148 dpm/fmol, american radiolabeled chemicals, saint louis, usa) in homogenates (10–30\xa0μg of protein).']	N/A	N/A	[('CHEBI_29238', 'tritium atom', 136, '3H'), ('CHEBI_85300', 'N(1),N(8)-bis(sinapoyl)-spermidine', 141, 'N ‐methylscopolamine'), ('CHEBI_29238', 'tritium atom', 164, '3H'), ('CHEBI_16412', 'lipopolysaccharide', 168, 'NMS')]
PMC4825102	2/2016	S97-PMC4825102	['from Lps-treated raw264·7 Macrophages)(144)Resveratrol (0·1–1 µm) for 24 hprevents hyperpermeability; ↑No Production; ↑Enos activityhigh-Glucose-treated baec(145)36 % fat supplemented with 0·37 % Resveratrol↑Placental Dha uptake; ↑ha u activity; ↑mrna Expression of Dha receptorshigh-fat diet (36 % fat supplementated with 0·37 % Resveratrol) in Pregnant Non-Human Primates(193)Tyr (0·1–10 µm) for 1 h pretreatment↑adiponectin; ↑Ppar γ activity; ↓jnk activationhuman Adipocytes tnf α treated(149)Tyr, or ol, or ht, or tax (50 µmeach) for 24 h↓Proliferation and migration; ht and tax↓Vegfr2, Erk1/2 and jnk phosphorylationvegf-treated huvec(150)\n↑, increases; ↓, decreases; nod, non-obese diabetic; Jnk, C-Jun n -terminal kinase; Foxo1, Forkhead Box Protein O1; Gsis, Glucose-stimulated Insulin secretion; Camp, Cyclic Amp; Pka, protein kinase a; Egcg, Epigallocatechin-3-Gallate; Irs1/2, Insulin Receptor Substrate 1/2; ampk, amp-activated protein kinase; c3g, cyanidin-3-Glucoside; sirt-1, Sirtuin 1; stz, Streptozotocin; Pdx1, Pancreatic and Duodenal Homeobox-1; pca, Protocatechuic Acid; t2d, type 2 diabetes; Akt, Protein Kinase B; Ins-1, Insulin 1; gk, Glycerol kinase; P38 Mapk, P38 Mitogen-activated protein kinase; hba1c, glycated Hb; pi3k, Phosphatidylinositol-3-Kinase; Erk1/2, Extracellular Signal-Regulated Kinase; Lps, Lipopolysaccharides; No, Nitric Oxide; Enos, Endothelial no synthase; baec, Bovine Artery Endothelial Cells; tyr, tyrosol; ol, Oleuropein; ht, Hydroxytyrosol; Tax, Taxifolin; Vegfr2, Vascular Endothelial Growth Factor Receptor 2; Vegf, Vascular Endothelial Growth Factor; huvec, Human Umbilical Vein Endothelial Cells.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 5, 'LPS'), ('CL_0000235', 'macrophage', 26, 'macrophages'), ('CHEBI_27881', 'resveratrol', 43, 'Resveratrol'), ('GO_0032902', 'nerve growth factor production', 103, 'NO production'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 119, 'eNOS'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('CHEBI_27881', 'resveratrol', 196, 'resveratrol'), ('UBERON_0001987', 'placenta', 208, 'Placental'), ('CHEBI_17874', 'dihydrozeatin', 218, 'DHA'), ('GO_0010467', 'gene expression', 252, 'expression'), ('CHEBI_17874', 'dihydrozeatin', 266, 'DHA'), ('CHEBI_27881', 'resveratrol', 330, 'resveratrol'), ('GO_0007565', 'female pregnancy', 346, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 355, 'non'), ('NCBITaxon_9606', 'Homo sapiens', 359, 'human'), ('NCBITaxon_33208', 'Metazoa', 365, 'primates'), ('CHEBI_9754', 'tris', 378, 'Tyr'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 429, 'PPAR'), ('CL_0000136', 'fat cell', 467, 'adipocytes'), ('CHEBI_9754', 'tris', 496, 'Tyr'), ('GO_0008283', 'cell proliferation', 543, 'Proliferation'), ('PR_000017279', 'testis-specific basic protein Y 1', 583, 'VEGFR2'), ('PR_000007164', 'general transcription and DNA repair factor IIH helicase subunit XPD', 591, 'ERK1'), ('PR_000009211', 'lysine-specific demethylase 3A', 698, 'JNK'), ('PR_000004968', 'calretinin', 703, 'c-Jun'), ('PR_000017653', 'zinc finger protein ZFPM2', 729, 'Foxo1'), ('PR_000007620', 'forkhead box protein E3', 736, 'forkhead box protein O1'), ('PR_000008294', 'glutathione S-transferase A1', 761, 'GSIS'), ('CHEBI_17234', 'glucose', 767, 'glucose'), ('PR_000045358', 'insulin family protein', 786, 'insulin'), ('CHEBI_17489', "3',5'-cyclic AMP", 805, 'cAMP'), ('CHEBI_27840', '2,4-dimethylaniline', 811, 'cyclic AMP'), ('PR_000012724', 'phosphatidylinositol 3-kinase regulatory subunit alpha', 823, 'PKA'), ('CHEBI_42298', 'HEPPS', 846, 'EGCG'), ('CHEBI_75272', 'splitomicin', 852, 'epigallocatechin-3-gallate'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 880, 'IRS1'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 888, 'insulin receptor substrate 1'), ('CHEBI_35435', "4'-aminobiphenyl-4-ol", 970, '3-glucoside'), ('PR_000015711', 'STAM-binding protein', 991, 'sirtuin 1'), ('CHEBI_9288', 'streptozocin', 1007, 'streptozotocin'), ('PR_000012525', 'pyridoxal phosphate phosphatase', 1023, 'PDX1'), ('PR_000014700', 'serpin B9', 1029, 'pancreatic'), ('UBERON_0001264', 'pancreas', 1029, 'pancreatic'), ('PR_000006629', 'docking protein 2', 1044, 'duodenal homeobox-1'), ('UBERON_0001245', 'anus', 1044, 'duodenal'), ('CHEBI_15425', 'proclavaminic acid', 1070, 'protocatechuic acid'), ('PR_000003908', 'aflatoxin B1 aldehyde reductase member 2', 1113, 'Akt'), ('PR_000013504', 'periodic tryptophan protein 1', 1118, 'protein kinase B'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 1136, 'INS-1'), ('PR_000009078', 'integrator complex subunit 9', 1143, 'insulin 1'), ('CHEBI_17754', 'glycerol', 1158, 'glycerol'), ('PR_000001440', 'galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1', 1175, 'p38 MAPK'), ('PR_000000123', 'ribosomal protein S6 kinase beta-1', 1185, 'p38 mitogen'), ('CHEBI_52290', 'mitogen', 1189, 'mitogen'), ('PR_000008609', 'hexokinase-2', 1239, 'Hb'), ('CHEBI_28874', 'phosphatidylinositol', 1249, 'phosphatidylinositol'), ('PR_000013390', '26S proteasome non-ATPase regulatory subunit 8', 1249, 'phosphatidylinositol-3'), ('CHEBI_37972', 'phosphorus-32 atom', 1270, '3'), ('PR_000009210', 'Jun dimerization protein 2', 1272, 'kinase'), ('PR_000007164', 'general transcription and DNA repair factor IIH helicase subunit XPD', 1280, 'ERK1'), ('GO_0005576', 'extracellular region', 1288, 'extracellular'), ('PR_000007140', 'epsin-3', 1288, 'extracellular signal-regulated kinase'), ('CHEBI_16412', 'lipopolysaccharide', 1327, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 1332, 'lipopolysaccharides'), ('CHEBI_16382', 'iodide', 1353, 'NO'), ('CHEBI_16480', 'nitric oxide', 1357, 'nitric oxide'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 1371, 'eNOS'), ('UBERON_0001986', 'endothelium', 1377, 'endothelial'), ('CL_1001578', 'vagina squamous cell', 1408, 'bovine artery endothelial cells'), ('NCBITaxon_33208', 'Metazoa', 1408, 'bovine'), ('UBERON_0001637', 'artery', 1415, 'artery'), ('UBERON_0001986', 'endothelium', 1422, 'endothelial'), ('CHEBI_31963', 'Paramethasone acetate', 1459, 'oleuropein'), ('CHEBI_68888', 'benarthin', 1475, 'hydroxytyrosol'), ('PR_000016933', 'transmembrane O-methyltransferase', 1491, 'Tax'), ('PR_000016288', 'homeobox protein TGIF1', 1496, 'taxifolin'), ('PR_000017279', 'testis-specific basic protein Y 1', 1507, 'VEGFR2'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 1515, 'vascular endothelial growth factor receptor 2'), ('UBERON_0001986', 'endothelium', 1524, 'endothelial'), ('PR_000017279', 'testis-specific basic protein Y 1', 1562, 'VEGF'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1568, 'vascular endothelial growth factor'), ('UBERON_0001986', 'endothelium', 1577, 'endothelial'), ('NCBITaxon_9606', 'Homo sapiens', 1611, 'human'), ('CL_0010002', 'epithelial cell of umbilical artery', 1617, 'umbilical vein endothelial cells'), ('UBERON_0002066', 'umbilical vein', 1617, 'umbilical vein'), ('UBERON_0001986', 'endothelium', 1632, 'endothelial')]
PMC4889866	5/2016	S40-PMC4889866	['these included synthetic bacterial lipoprotein (Pam3Csk4) that is recognized by Tlr1-2; a synthetic analog of Double Stranded rna for Tlr3; ultrapure Lps for Tlr4; and r848, which is activated via the Tlr7/Tlr8 Signaling Pathway.']	N/A	N/A	[('PR_000012200', 'transmembrane prolyl 4-hydroxylase', 48, 'PAM3csk4'), ('PR_000001155', 'Toll-like receptor 4', 80, 'TLR1'), ('SO_0000985', 'double', 110, 'double stranded'), ('PR_000001155', 'Toll-like receptor 4', 134, 'TLR3'), ('CHEBI_16412', 'lipopolysaccharide', 150, 'LPS'), ('PR_000001155', 'Toll-like receptor 4', 158, 'TLR4'), ('GO_0061744', 'motor behavior', 201, 'TLR7 ...'), ('PR_000001155', 'Toll-like receptor 4', 201, 'TLR7'), ('GO_0034150', 'toll-like receptor 6 signaling pathway', 206, 'TLR8 signaling pathway'), ('PR_000001155', 'Toll-like receptor 4', 206, 'TLR8')]
PMC4889866	5/2016	S44-PMC4889866	['the concentrations of the ligands used for this experiment are as follows: 10\u2009 μ g/ml of pam3csk4, 10\u2009 μ g/ml of Poly(i:c) directly administered, 20\u2009ng/ml of Lps, and 10\u2009 μ g/ml of r848 (invivogen, san diego, ca).']	N/A	N/A	[('CHEBI_37311', 'einsteinium molecular entity', 113, 'poly'), ('CHEBI_16412', 'lipopolysaccharide', 158, 'LPS')]
PMC4896250	4/2016	S2381-PMC4896250	['a549 cells were cultured in rpmi1640 containing 10% fbs, cells were treated for 4 hr with Lps (100 ng/ml) and p25 Tio2 Nanoparticles (10 ug/ml, 50 ug/ml, 250 ug/ml) and medium as control.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 90, 'LPS'), ('CHEBI_81383', 'Dihydroabietic acid', 114, 'TiO2'), ('CHEBI_51029', 'nedocromil(2-)', 119, 'nanoparticles')]
PMC4896250	4/2016	S2384-PMC4896250	['results: the viability of Hadscs and a549 cells were not affected by the treatment of Lps and p25 Tio2.']	N/A	N/A	[('CL_0000855', 'sensory hair cell', 26, 'hADSCs'), ('CHEBI_16412', 'lipopolysaccharide', 86, 'LPS'), ('CHEBI_81383', 'Dihydroabietic acid', 98, 'TiO2')]
PMC4896250	4/2016	S2385-PMC4896250	['Lps increased the Expression of Il-8 and tnfa mrnas, but decreased the Expression of Il-10 in Hadscs.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('GO_0010467', 'gene expression', 18, 'expression'), ('PR_000001470', 'interleukin-28B', 32, 'IL-8'), ('GO_0010467', 'gene expression', 71, 'expression'), ('PR_000001470', 'interleukin-28B', 85, 'IL-10'), ('CL_0000855', 'sensory hair cell', 94, 'hADSCs')]
PMC4896250	4/2016	S2387-PMC4896250	['in a549 cells, Lps and p25 Tio2 decreased the Expression of Il-1A and Il-10 mrnas, but did not affect the Expression of Il-8 and tnfa mrnas.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 15, 'LPS'), ('CHEBI_81383', 'Dihydroabietic acid', 27, 'TiO2'), ('GO_0010467', 'gene expression', 46, 'expression'), ('PR_000001371', 'interleukin-13 receptor subunit alpha-1', 60, 'IL-1a'), ('PR_000001470', 'interleukin-28B', 70, 'IL-10'), ('GO_0010467', 'gene expression', 106, 'expression'), ('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 120, 'IL')]
PMC4896250	4/2016	S3079-PMC4896250	['method: primary Human Middle Ear Epithelial Cells (hmeec) were exposed to Der F crude body extract, Lps or both in different sequences, and the magnitude of each immunologic response produced by the hmeec was compared.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 16, 'human'), ('CL_0002365', 'medullary thymic epithelial cell', 22, 'middle ear epithelial cells'), ('UBERON_0015813', 'middle ear epithelium', 22, 'middle ear epithelial'), ('PR_000006266', 'dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1', 74, 'Der f'), ('CHEBI_16412', 'lipopolysaccharide', 100, 'LPS')]
PMC4896250	4/2016	S3085-PMC4896250	['the muc proteins level were increased by the pretreatment of Der F followed by Lps and decreased by the treatment of Sb203580 (P38 Inhibitor) and bay (nf-Kb inhibitor).']	N/A	N/A	[('PR_000006266', 'dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1', 61, 'Der f'), ('CHEBI_16412', 'lipopolysaccharide', 79, 'LPS'), ('CHEBI_8977', 'SB 206553', 117, 'SB203580'), ('PR_000000123', 'ribosomal protein S6 kinase beta-1', 127, 'p38'), ('CHEBI_35222', 'inhibitor', 131, 'inhibitor'), ('PR_000003676', 'actin, cytoplasmic 1', 153, '-kB')]
PMC4896250	4/2016	S4127-PMC4896250	['methods: male balb/c Mice were randomly divided into three groups, control, Lps, and Lps-c group.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 21, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 76, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 85, 'LPS')]
PMC4896250	4/2016	S4128-PMC4896250	['ali was induced by Lps ip injection (5 mg/kg).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 19, 'LPS')]
PMC4896250	4/2016	S4129-PMC4896250	['the Sonic Hedgehog Inhibitor Cyclopamine was given to the Lps-c group (50 mg/kg) at 30 min after Lps injection.']	N/A	N/A	[('PR_000014841', 'sonic hedgehog protein', 4, 'sonic hedgehog'), ('CHEBI_35222', 'inhibitor', 19, 'inhibitor'), ('CHEBI_4046', 'cyproheptadine', 29, 'cyclopamine'), ('CHEBI_16412', 'lipopolysaccharide', 58, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 97, 'LPS')]
PMC4896250	4/2016	S5164-PMC4896250	['this Immune Responses are mediated Lps recognition, and the source of it is gram negative bacteria in hdm.']	N/A	N/A	[('GO_0006955', 'immune response', 5, 'immune responses'), ('UBERON_0002405', 'immune system', 5, 'immune'), ('CHEBI_16412', 'lipopolysaccharide', 35, 'LPS')]
PMC4896250	4/2016	S6342-PMC4896250	['phytohemagglutinin (Pha) and Lipopolysaccharide (Lps) were used as positive controls.']	N/A	N/A	[('CHEBI_34926', 'Pitrazepin', 20, 'PHA'), ('CHEBI_16412', 'lipopolysaccharide', 29, 'Lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 49, 'LPS')]
PMC4896250	4/2016	S7234-PMC4896250	['methods: na and Neutrophilic asthma Dexamethasone intervention(nad) Mice were sensitized by Lps and ova Airway delivery.']	N/A	N/A	[('CL_0000775', 'neutrophil', 16, 'neutrophilic'), ('CHEBI_41879', 'dexamethasone', 36, 'dexamethasone'), ('NCBITaxon_10088', 'Mus <genus>', 68, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 92, 'LPS'), ('UBERON_0001005', 'respiratory airway', 104, 'airway')]
PMC4896250	4/2016	S8005-PMC4896250	['the above Mice were treated as fowllow: Mice in na group or Naag group were sensitized by a Mixture consists 100ug of ovalbumin(ova,grade v) and 0.1ug of Lipopolysaccharide(Lps) via Airway delivery on the experiment days 0,6,13.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 40, 'Mice'), ('CHEBI_13389', 'NAD', 60, 'NAAG'), ('CHEBI_60004', 'mixture', 92, 'mixture'), ('CHEBI_16412', 'lipopolysaccharide', 154, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 173, 'LPS'), ('UBERON_0001005', 'respiratory airway', 182, 'airway')]
PMC4896250	4/2016	S8007-PMC4896250	['in the case of intervention of ag490 encountering sentisization with ova and Lps, we injected the Mice with ag490 30 minutes before they were sensitised through Airway dilivery.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 77, 'LPS'), ('NCBITaxon_10088', 'Mus <genus>', 98, 'mice'), ('UBERON_0001005', 'respiratory airway', 161, 'airway')]
PMC4896250	4/2016	S8173-PMC4896250	['na and Naa Mice were sensitized by low-dose Lipopolysaccharide(Lps) and Ovalbumin(ova) Airway delivery on days 0, 6 and 13.']	N/A	N/A	[('CHEBI_32145', 'sodium hydroxide', 7, 'NAA'), ('NCBITaxon_10088', 'Mus <genus>', 11, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 44, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 63, 'LPS'), ('CHEBI_83268', 'oxathiapiprolin', 72, 'ovalbumin'), ('UBERON_0001005', 'respiratory airway', 87, 'airway')]
PMC5093279	10/2016	S100-PMC5093279	['most of the behavioral impairments in offspring from mothers treated with Poly(I:C) are observed with Lps [77].']	N/A	N/A	[('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 74, 'poly(I:C'), ('CHEBI_16412', 'lipopolysaccharide', 102, 'LPS')]
PMC5093279	10/2016	S102-PMC5093279	['very low doses of Lps administered to rhesus monkeys at the end of Gestation also induce ppi impairment in offspring [82].']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 18, 'LPS'), ('GO_0007565', 'female pregnancy', 67, 'gestation')]
PMC5093279	10/2016	S108-PMC5093279	['the decreased number of reelin-positive cells, together with Gad67- and Parvalbumin-positive cells, is found in the developing hippocampus and Prefrontal Cortex of offspring from Lps-injected mothers [93–96].']	N/A	N/A	[('PR_000007780', 'gamma-aminobutyric acid receptor subunit pi', 61, 'GAD67'), ('PR_000004075', 'annexin A2', 72, 'parvalbumin'), ('UBERON_0000451', 'prefrontal cortex', 143, 'prefrontal cortex'), ('CHEBI_16412', 'lipopolysaccharide', 179, 'LPS')]
PMC5093279	10/2016	S116-PMC5093279	['Lps, a Gram-negative bacteria Cell Wall component, activates Tlr4.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('NCBITaxon_9606', 'Homo sapiens', 7, 'gram'), ('GO_0005618', 'cell wall', 30, 'cell wall'), ('PR_000001155', 'Toll-like receptor 4', 61, 'TLR4')]
PMC5093279	10/2016	S122-PMC5093279	['in summary, mia triggered by active pathogens or Noninfectious endotoxins (Poly(I:C) and Lps) administered during Pregnancy recapitulates asd-like behaviors and neurobiological alterations in offspring.']	N/A	N/A	[('GO_0008283', 'cell proliferation', 49, 'noninfectious'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 75, 'poly(I:C'), ('CHEBI_16412', 'lipopolysaccharide', 89, 'LPS'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy')]
PMC5283658	1/2017	S224-PMC5283658	['Lp by itself also inhibited Il-6 Expression in atms, which is independent of the Adipocyte size.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LP'), ('PR_000001470', 'interleukin-28B', 28, 'IL-6'), ('GO_0010467', 'gene expression', 33, 'expression'), ('CL_0000136', 'fat cell', 81, 'adipocyte')]
PMC5332602	3/2017	S108-PMC5332602	['caption (fig): fig\xa06\xa0\n\nSerum Lps levels of protein-deficient (a to d) and -sufficient (a and e to g) Hifm/hrv-infected Pigs.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 23, 'Serum'), ('CHEBI_16412', 'lipopolysaccharide', 29, 'LPS'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 101, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 119, 'pigs')]
PMC5332602	3/2017	S109-PMC5332602	['Lps levels in Serum samples from protein-deficient and -sufficient hifm/Hrv-infected Pigs ( n = 4 to 7) were determined with hek-blue Lps detection kit 2 (invivogen, ca).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('UBERON_0001977', 'blood serum', 14, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 72, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 85, 'pigs'), ('CHEBI_16412', 'lipopolysaccharide', 134, 'LPS')]
PMC5332602	3/2017	S255-PMC5332602	['evaluation of Serum Lps levels.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('CHEBI_16412', 'lipopolysaccharide', 20, 'LPS')]
PMC5332602	3/2017	S256-PMC5332602	['to measure Lps levels in Serum samples from Pigs, we used hek-blue Lps detection kit 2 (invivogen, ca) according to the manufacturer’s recommendations.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 11, 'LPS'), ('UBERON_0001977', 'blood serum', 25, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 44, 'pigs'), ('CHEBI_16412', 'lipopolysaccharide', 67, 'LPS')]
PMC5332602	3/2017	S279-PMC5332602	['the frequencies of cell populations in flow cytometry and Serum Glucose, protein, albumin, Lps, Vitamin A ands E, and Selenium levels were compared among groups with the kruskal-wallis rank sum and mann-whitney (nonparametric) tests.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('CHEBI_16412', 'lipopolysaccharide', 91, 'LPS'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 111, 'E'), ('CHEBI_27568', 'selenium atom', 118, 'selenium')]
PMC5482199	2/2017	S34-PMC5482199	['Lps-induced Cytokine Production\nHuman Cbmcs and pb Mcs (pbmcs) were incubated with Lipopolysaccharide (Lps) for 48\xa0h at 37°c before supernatants were collected.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 0, 'LPS'), ('GO_0001814', 'negative regulation of antibody-dependent cellular cytotoxicity', 12, 'cytokine production'), ('NCBITaxon_10088', 'Mus <genus>', 32, 'Human'), ('CL_0000979', 'IgG memory B cell', 38, 'CBMCs'), ('CL_0000186', 'myofibroblast cell', 51, 'MCs'), ('CHEBI_16412', 'lipopolysaccharide', 83, 'lipopolysaccharide'), ('CHEBI_16412', 'lipopolysaccharide', 103, 'LPS')]
PMC5482199	2/2017	S35-PMC5482199	['under the same time and temperature conditions, Cbmcs were also cultured in the presence of either anti-Il-10 (Il-10 neutralizing) Antibody or Il-12 alone or with Lps.']	N/A	N/A	[('CL_0000979', 'IgG memory B cell', 48, 'CBMCs'), ('PR_000001470', 'interleukin-28B', 104, 'IL-10'), ('PR_000001470', 'interleukin-28B', 111, 'IL-10'), ('GO_0042571', 'immunoglobulin complex, circulating', 131, 'antibody'), ('PR_000001470', 'interleukin-28B', 143, 'IL-12'), ('CHEBI_16412', 'lipopolysaccharide', 163, 'LPS')]
PMC5482199	2/2017	S63-PMC5482199	['the Production Of Ifnγ by Human Cbmcs was of the order of 5% of that observed with pbmcs from Adults when accessory cells were stimulated with Lps (figure 1a, left panel).']	N/A	N/A	[('GO_0032508', 'DNA duplex unwinding', 4, 'production of IFNγ'), ('PR_000008920', 'interferon alpha-7', 18, 'IFNγ'), ('NCBITaxon_9606', 'Homo sapiens', 26, 'human'), ('CL_0000979', 'IgG memory B cell', 32, 'CBMCs'), ('UBERON_0007023', 'adult organism', 94, 'adults'), ('CHEBI_16412', 'lipopolysaccharide', 143, 'LPS')]
PMC5482199	2/2017	S65-PMC5482199	['culturing Lps-stimulated Cbmcs in the presence of an anti-Il-10 neutralizing Antibody resulted in an increase in Ifnγ Production (figure 1b).']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 10, 'LPS'), ('CL_0000979', 'IgG memory B cell', 25, 'CBMCs'), ('PR_000001470', 'interleukin-28B', 58, 'IL-10'), ('GO_0042571', 'immunoglobulin complex, circulating', 77, 'antibody'), ('GO_0032608', 'interferon-beta production', 113, 'IFNγ production'), ('PR_000008920', 'interferon alpha-7', 113, 'IFNγ')]
PMC5482199	2/2017	S66-PMC5482199	['the addition of exogenous Il-12 to Lps-induced cmbcs overcame the inability of the cells to produce Ifnγ (figure 1c).']	N/A	N/A	[('PR_000001470', 'interleukin-28B', 26, 'IL-12'), ('CHEBI_16412', 'lipopolysaccharide', 35, 'LPS'), ('PR_000008920', 'interferon alpha-7', 100, 'IFNγ')]
PMC5482199	2/2017	S68-PMC5482199	['caption (fig): figure 1\ndeficient Production Of Ifnγ by Human Cbmcs is a function of altered cytokine milieu\n( a ) reduced Production Of Ifnγ and il-12 but increased Synthesis Of Il-10 by Human Cbmcs compared with Adult pbmcs was observed in response to Lps (30 ng/ml).']	N/A	N/A	[('GO_0032508', 'DNA duplex unwinding', 34, 'production of IFNγ'), ('PR_000008920', 'interferon alpha-7', 48, 'IFNγ'), ('NCBITaxon_9606', 'Homo sapiens', 56, 'human'), ('CL_0000979', 'IgG memory B cell', 62, 'CBMCs'), ('GO_0032508', 'DNA duplex unwinding', 123, 'production of IFNγ'), ('PR_000008920', 'interferon alpha-7', 137, 'IFNγ'), ('GO_0034205', 'amyloid-beta formation', 166, 'synthesis of IL-10'), ('PR_000001470', 'interleukin-28B', 179, 'IL-10'), ('NCBITaxon_9606', 'Homo sapiens', 188, 'human'), ('CL_0000979', 'IgG memory B cell', 194, 'CBMCs'), ('UBERON_0007023', 'adult organism', 214, 'adult'), ('CHEBI_16412', 'lipopolysaccharide', 254, 'LPS')]
PMC5482199	2/2017	S69-PMC5482199	['( b ) neutralization of Il-10 with an anti-Il-10 monoclonal Antibody (10 μg/ml) resulted in a significant increase in ifnγ Production by Lps-Stimulated (30 ng/ml) Cbmcs.']	N/A	N/A	[('PR_000001470', 'interleukin-28B', 24, 'IL-10'), ('PR_000001470', 'interleukin-28B', 43, 'IL-10'), ('GO_0042571', 'immunoglobulin complex, circulating', 60, 'antibody'), ('GO_0007128', 'meiotic prophase I', 123, 'production'), ('CHEBI_16412', 'lipopolysaccharide', 137, 'LPS'), ('GO_0042475', 'odontogenesis of dentin-containing tooth', 141, '... stimulated'), ('CL_0000979', 'IgG memory B cell', 163, 'CBMCs')]
PMC5482199	2/2017	S70-PMC5482199	['( c ) addition of exogenous recombinant Human Il-12 (2 μg/ml) increased the Ifnγ synthesis by Lps-stimulated Cbmcs.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 40, 'human'), ('PR_000001470', 'interleukin-28B', 46, 'IL-12'), ('PR_000008920', 'interferon alpha-7', 76, 'IFNγ'), ('CHEBI_16412', 'lipopolysaccharide', 94, 'LPS'), ('CL_0000979', 'IgG memory B cell', 109, 'CBMCs')]
